Thiazole urea derivative and application thereof

A novel thiazole urea derivative is developed to target Polθ in cancer cells, addressing the lack of effective Polθ inhibitors by inhibiting DNA repair and inducing cell death, particularly in HRD tumors, offering a solution for PARP resistance and improved cancer treatment.

CN119060045APending Publication Date: 2024-12-03HANGZHOU BIO CREATIVITY PHARM TECH CO LTD

Patent Information

Application Number
CN202410710503.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-06-02
Filing Date
2024-06-03
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Current research on Polθ inhibitors is in its early stages, and no drugs have been approved for marketing, with a significant unmet clinical need for effective treatments for tumors or cancers, particularly in patients with HRD and PARP inhibitor resistance.

Method used

Development of a novel thiazole urea derivative and its isomers, solvates, isotopic derivatives, or pharmaceutically acceptable salts, which exhibit potent Polθ inhibitory activity, targeting the MMEJ pathway in cancer cells to inhibit DNA repair and induce cell death.

Benefits of technology

The thiazole urea derivatives effectively inhibit Polθ, potentially overcoming PARP inhibitor resistance and providing a synergistic tumor-killing effect, especially in HRD tumors, including breast, ovarian, and lung cancers.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004873874510000011
    Figure BDA0004873874510000011
  • Figure BDA0004873874510000021
    Figure BDA0004873874510000021
  • Figure BDA0004873874510000022
    Figure BDA0004873874510000022
Patent Text Reader

Abstract

The invention discloses thiazole urea derivatives and application thereof, and particularly relates to the derivatives and prodrugs, tautomers, optical isomers, solvates, isotope derivatives or pharmaceutically acceptable salts thereof. Based on a Pol theta target, a series of thiazole urea derivatives with novel structures are developed, the compounds are subjected to a series of related biological tests, and test results show that the compounds have remarkable Pol theta inhibitory activity, can be used for treating and preventing cancers and belong to the field of medicinal chemistry.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a thiazole urea derivative and use thereof. The derivative and its prodrug, tautomer, optical isomer, solvate, isotope derivative or pharmaceutically acceptable salt have Polθ inhibitory activity and can be used for treating and preventing cancer, belonging to the field of pharmaceutical chemistry. Background Art

[0002] Common forms of DNA damage include single-strand breaks, double-strand breaks (DSBs), and base damage. Among them, DSB damage is the most serious. If DSBs cannot be repaired in time, chromosomes will show abnormalities such as breakage, deletion, and rearrangement. Therefore, the timely repair of DSBs plays an important role in maintaining genome stability, ensuring cell survival, and inhibiting the occurrence and development of tumors. The repair of double-stranded DNA breaks can be roughly divided into three main pathways: homologous recombination repair (HR), a repair process that uses double-stranded DNA homologous to damaged DNA as a template to synthesize DNA, with high fidelity and low mismatch repair rate; non-homologous end joining (NHEJ), which captures the damaged ends of broken double-stranded DNA and directly connects the damaged ends using protein interactions. It is an error-prone repair process; micro-homologous end joining (MMEJ), a more extensive and error-prone end joining mechanism, also known as alternative end joining (alt-EJ), is driven by the annealing of micro-homologous sequences on the DNA end side.

[0003] Under normal circumstances, MMEJ, as an alternative repair to HR, occurs at a very low rate, but in cells with HR defects, MMEJ becomes the main DSB repair method. For example, in cancer cells with BRCA gene defects, HR repair is impaired, and MMEJ becomes the main repair pathway for DSB. In this process, DNA polymerase θ (Polθ) plays a very critical role. Polθ replaces RPA at the resected DSB to promote the annealing of micro-homologous ssDNA, and then synthesizes DNA to fill the resected gap and complete the connection of the damaged ends. Polθ is hardly expressed in normal tissues, but is highly expressed in many tumor types (such as breast cancer, ovarian cancer, colorectal cancer, and lung cancer), and its upregulation is associated with poor cancer prognosis. Homologous recombination repair deficiency (HRD) is common in these tumors, and tumor suppressor genes related to DNA repair (including BRCA1, BRCA2, ATM, and FANCD2) are missing.

[0004] Research on Polθ provides a new targeted strategy for tumor treatment. In cancer cells with damaged or inactivated HR and NHEJ, the repair of DSB is highly dependent on the MMEJ process. If the activity of Polθ is inhibited, the cells will lose the ability to perform MMEJ, making it impossible for DSB to be repaired in time, and long-term accumulation will lead to cancer cell death. Therefore, for tumor patients carrying HRD such as BRCA1 / 2 mutations, Polθ inhibitors can be used in combination with PARP inhibitors to achieve a synergistic tumor-killing effect; in addition, patients receiving maintenance treatment with PARP inhibitors will develop resistance, which may be due to gene mutations that partially restore HR pathway activity, such as the loss of TP53BP1. At this time, the HR repair method is mainly Polθ-dependent MMEJ, so Polθ inhibitors can also overcome PARP inhibitor resistance and bring treatment benefits to more patients.

[0005] At present, the research on Polθ inhibitors is in the early stage, and no related drugs have been approved for marketing. Only one inhibitor, Artios' ART4215, has entered the Phase II clinical study (WO2021028643, WO2021028644A1, WO2021028670). There are major unmet clinical needs, so the development of new and efficient Polθ inhibitors has great scientific research significance and clinical value. The present invention aims to provide a novel thiazole urea derivative and its use, the described compound has excellent Polθ inhibitory activity and can be used as a Polθ inhibitor for the treatment of related tumors or cancers. Summary of the invention

[0006] The present invention aims to provide a novel thiazole urea derivative, which can be used as a Polθ inhibitor for the treatment of tumors or cancer. To solve the above technical problems, the present invention adopts the following technical solutions:

[0007] A thiazole urea derivative and its isomers, solvates, isotopic derivatives or pharmaceutically acceptable salts, which is a compound represented by formula (I):

[0008]

[0009] in:

[0010] R 1 is selected from 4-12 membered heterocyclic group, 5-14 membered heteroaryl group or C 6-12 Aryl; the 4-12 membered heterocyclic group, 5-14 membered heteroaryl and C 6-12 The aryl group is unsubstituted or substituted by one or more of the following substituents: halogen, cyano, hydroxyl, difluoromethoxy, trifluoromethoxy, amino, thiol, trifluoromethylthio, oxo, -NH-C(O)C 1-6Alkyl, -NH-C(O)-C 3-6 Cycloalkyl, -C(O)C 1-3 Alkyl, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkylsulfone, C 1-6 Alkylamino, C 1-6 Alkylthio, 4-10 membered heterocyclic group, C 6-12 Aryl, 5-14 membered heteroaryl;

[0011] R 2 and R 3 are each independently selected from hydrogen, C 1-6 Alkyl or C 3-6 Cycloalkyl;

[0012] R 4 is selected from hydrogen, halogen, cyano, hydroxy, difluoromethoxy, trifluoromethoxy, amino, C 1-6 Alkyl, C 3-8 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkylsulfone, C 1-6 Alkylamino, C 1-6 Alkylthio, 4-6 membered heterocyclic group;

[0013] Ring A is selected from:

[0014]

[0015] Ring B is selected from a benzene ring, a pyridine ring, a pyrimidine ring, a pyrazine ring or a pyridone ring;

[0016] R 5 Selected from halogen, cyano, hydroxyl, amino, thiol, oxo, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 1-6 Alkylthio, C 1-6 Alkylsulfone, C 6-12 aryl, 4-10 membered heterocyclic group or 5-14 membered heteroaryl; said C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 1-6 Alkylthio, C1-6 Alkylsulfone, 4-10 membered heterocyclic group, C 6-12 Aryl and 5-14 membered heteroaryl are unsubstituted or substituted by one or more of the following substituents: halogen, cyano, hydroxyl, thiol, amino, oxo, -NH-C(O)C 1-3 Alkyl, -C(O)NH2, -C(O)-NH-C 1-3 Alkyl, -C(O)C 1-3 Alkyl, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 1-6 Alkylthio, C 1-6 Alkylsulfone, C 6-12 Aryl, C 6-12 Aryl, 4-10 membered heterocyclyl or 5-14 membered heteroaryl;

[0017] n is selected from 0, 1, 2, 3, 4 or 5;

[0018] Furthermore, the thiazolyl urea derivatives and their isomers, solvates, isotopic derivatives or pharmaceutically acceptable salts thereof of the present invention, R 1 Selected from:

[0019]

[0020] Furthermore, the thiazolyl urea derivatives and their isomers, solvates, isotopic derivatives or pharmaceutically acceptable salts thereof of the present invention, R 2 and R 3 Each is preferably selected from hydrogen;

[0021] Furthermore, the thiazolyl urea derivatives and their isomers, solvates, isotopic derivatives or pharmaceutically acceptable salts thereof of the present invention, R 4 Preferably selected from hydrogen, fluorine, methyl, cyano, difluoromethyl or trifluoromethyl;

[0022] Furthermore, the thiazolyl urea derivatives and their isomers, solvates, isotopic derivatives or pharmaceutically acceptable salts thereof of the present invention, R 5 Selected from:

[0023]

[0024] Furthermore, the present invention also provides thiazole urea derivatives and their isomers, solvates, isotope derivatives or pharmaceutically acceptable salts, which are compounds having the following general structural formula (I) or pharmaceutically acceptable salts thereof:

[0025]

[0026] In the formula, R 2 and R 3 are each independently selected from hydrogen or C 1-6 alkyl;

[0027] Ring A is selected from: Wherein, * indicates that ring A is connected to the thiazole ring;

[0028] Preferably, in the above general structural formula (I), R 2 and R 3 are each independently selected from hydrogen.

[0029] Furthermore, the present invention also provides thiazole urea derivatives and their isomers, solvates, isotope derivatives or pharmaceutically acceptable salts, which are compounds having the following structural formula (II) or pharmaceutically acceptable salts thereof:

[0030]

[0031] In the formula, R 2 and R 3 are each independently selected from hydrogen or C 1-6 alkyl;

[0032] R 5 is selected from substituted or unsubstituted C 1-6 Alkyl, the C 1-6 The alkyl group may be substituted by one or more of the following substituents: halogen, hydroxyl or 4-10 membered heterocyclic group;

[0033] Ring A is selected from Wherein, * indicates that ring A is connected to the thiazole ring.

[0034] Preferably, in the above general structural formula (II), R 2 and R 3 are each independently selected from hydrogen.

[0035] Preferably, in the above general structural formula (II), R 5 Selected from

[0036] Furthermore, the present invention also provides thiazole urea derivatives and their isomers, solvates, isotope derivatives or pharmaceutically acceptable salts, which are compounds having the following general structural formula (III) or pharmaceutically acceptable salts thereof:

[0037]

[0038] In the formula, R 1 Selected from

[0039] R 2 and R 3 are each independently selected from hydrogen or C 1-6 alkyl;

[0040] Ring A is selected from Wherein, * indicates that ring A is connected to the thiazole ring.

[0041] Preferably, in the above general structural formula (III), R 2 and R 3 are each independently selected from hydrogen.

[0042] Furthermore, the thiazole urea derivatives and their isomers, solvates, isotopic derivatives or pharmaceutically acceptable salts thereof described in the present invention are preferably selected from the following structures:

[0043]

[0044]

[0045]

[0046]

[0047] The "isomers" described in the present invention include all stereoisomers, such as enantiomers and diastereomers. The compounds containing asymmetric carbon atoms in the present invention can be separated in an optically pure form or in a racemic form. The optically pure form can be resolved from a racemic mixture or synthesized by using chiral raw materials or chiral reagents.

[0048] The "pharmaceutically acceptable salts" of the present invention refer to salts of the compounds of the present invention, prepared from compounds with specific substituents discovered by the present invention and relatively non-toxic bases. When the derivatives of the present invention contain relatively acidic functional groups, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of base in a pure solution or a suitable inert solvent. Pharmaceutically acceptable base addition salts include, but are not limited to, sodium, potassium, calcium, magnesium salts, ammonium or organic amines. For example: alkali metal salts, alkaline earth metal salts, other metal salts, inorganic base salts, organic base salts, inorganic acid salts, lower alkane sulfonates, aryl sulfonates, organic acid salts, amino acid salts, etc. When the derivatives of the present invention contain relatively basic functional groups, the basic groups can be salted with one of 2-acetoxybenzoic acid, 2-hydroxyethanesulfonic acid, formic acid, acetic acid, ascorbic acid, benzenesulfonic acid, benzoic acid, bicarbonate, carbonic acid, citric acid, edetic acid, ethanedisulfonic acid, ethanesulfonic acid, fumaric acid, glucoheptose, gluconic acid, glutamic acid, glycolic acid, hydrobromic acid, hydrochloric acid, hydroiodide, hydroxynaphthalene, isethionic acid, lactic acid, lactose, dodecylsulfonic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, nitric acid, oxalic acid, pamoic acid, pantothenic acid, phenylacetic acid, phosphoric acid, polygalacturonic acid, propionic acid, salicylic acid, stearic acid, acetic acid, succinic acid, aminosulfonic acid, p-aminobenzenesulfonic acid, sulfuric acid, tannin, tartaric acid and p-toluenesulfonic acid;

[0049] In addition to the form of salts, compounds provided by the present invention also exist in prodrug forms. Prodrugs of compounds described herein easily undergo chemical changes under physiological conditions to be converted into compounds of the present invention. In addition, prodrugs can be converted to compounds of the present invention by chemical or biochemical methods in an in vivo environment.

[0050] The terms used in this article have the following meanings for compounds containing the above general structure:

[0051] The term "halogen" refers to fluorine, chlorine, bromine or iodine, preferably fluorine, chlorine or bromine.

[0052] The term "alkyl" refers to a straight-chain or branched saturated hydrocarbon group consisting of carbon atoms and hydrogen atoms, such as C1-C6 alkyl, including but not limited to methyl, ethyl, propyl (including n-propyl and isopropyl), butyl (including n-butyl, isobutyl, sec-butyl or tert-butyl), pentyl (including n-pentyl, isopentyl, neopentyl), n-hexyl, and 2-methylhexyl.

[0053] The term "oxo" refers to two hydrogen atoms at the same substitution position being replaced by the same oxygen atom to form a double bond, ie, =0.

[0054] The term "alkenyl" refers to a linear or branched unsaturated aliphatic hydrocarbon group consisting of carbon atoms and hydrogen atoms and having at least one double bond. The alkenyl group may contain 2 to 20 carbon atoms, preferably 2 to 10 carbon atoms (i.e., C2-10 Alkenyl), further preferably containing 2 to 8 carbon atoms (C 2-8 Alkenyl), more preferably containing 2 to 6 carbon atoms (i.e., C 2-6 alkenyl), 2-5 carbon atoms (i.e. C 2-5 alkenyl), 2-4 carbon atoms (i.e. C 2-4 alkenyl), 2-3 carbon atoms (i.e. C 2-3 alkenyl), 2 carbon atoms (i.e., C2 alkenyl), for example, "C 2-6 "Alkenyl" means that the group is an alkenyl group, and the number of carbon atoms in the carbon chain is between 2 and 6 (specifically 2, 3, 4, 5 or 6). Non-limiting examples of alkenyl include, but are not limited to, vinyl, 1-propenyl, 2-propenyl, 1-butenyl, isobutenyl and 1,3-butadienyl, etc.

[0055] The term "alkynyl" refers to a straight or branched unsaturated aliphatic hydrocarbon group consisting of carbon atoms and hydrogen atoms and having at least one triple bond. The alkynyl group may contain 2 to 20 carbon atoms, preferably 2 to 10 carbon atoms (i.e., C 2-10 Alkynyl), further preferably containing 2 to 8 carbon atoms (C 2-8 Alkynyl), more preferably containing 2 to 6 carbon atoms (i.e. C 2-6 Alkynyl), 2-5 carbon atoms (i.e. C 2-5 Alkynyl), 2-4 carbon atoms (i.e. C 2-4 Alkynyl), 2-3 carbon atoms (i.e. C 2-3 alkynyl), 2 carbon atoms (i.e., C2 alkynyl), for example, "C 2-6 "Alkynyl" means that the group is an alkynyl group, and the number of carbon atoms in the carbon chain is between 2 and 6 (specifically 2, 3, 4, 5 or 6). Non-limiting examples of alkynyl groups include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl and 1-butynyl, etc.

[0056] The term "cycloalkyl" refers to a monocyclic or bicyclic alkyl group composed of carbon atoms and hydrogen atoms, such as C3-C8 cycloalkyl, including but not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.

[0057] The term "alkoxy" refers to a straight or branched alkyl group connected by an oxygen atom, such as C1-C6 alkoxy, including but not limited to methoxy, ethoxy, n-propoxy (including n-propoxy and isopropoxy), butoxy (including n-butoxy, isobutoxy, sec-butoxy or tert-butoxy), pentoxy (including n-pentoxy, isopentoxy, neopentoxy), n-hexyloxy, 2-methylhexyloxy, etc.

[0058] The term "alkylamino" refers to an open-chain alkyl group containing a nitrogen atom, such as C1-C6 alkylamino, including but not limited to methylamino, ethylamino, isopropylamino, dimethylamino, methylethylamino, diethylamino and the like.

[0059] The term "alkylthio" means that the oxygen in the above-mentioned "alkoxy" is replaced by sulfur, that is, -S-alkyl, such as C1-C6 alkylthio. Representative examples include but are not limited to methylthio, ethylthio, propylthio, isopropylthio, butylthio, 1-methylpropylthio, tert-butylthio, pentylthio, 1,1-dimethylpropylthio, 1,2-dimethylpropylthio and the like.

[0060] The term "alkylsulfonyl" refers to a straight or branched chain alkyl group attached through a sulfone group, i.e., -SO 2- Alkyl, such as C1-C6 alkylsulfone, representative examples include but are not limited to methylsulfone, ethylsulfone, propylsulfone, isopropylsulfone, butylsulfone, 1-methylpropylsulfone, tert-butylsulfone, pentanylsulfone, 1,1-dimethylpropylsulfone, 1,2-dimethylpropylsulfone, and the like.

[0061] The term "aryl" refers to an all-carbon monocyclic or condensed polycyclic group of 6 to 16 carbon atoms, having a completely conjugated π-electron system, including but not limited to a benzene ring, a naphthalene ring, and an anthracene ring.

[0062] The term "heterocyclyl" refers to a saturated or partially unsaturated monocyclic, bicyclic or polycyclic hydrocarbon substituent, which is a non-aromatic structure and contains 3-20 ring atoms, wherein 1, 2, 3 or more ring atoms are selected from N, O or S, and the remaining ring atoms are C. Examples of monocyclic heterocyclyls include pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, dihydropyrrolyl, piperidinyl, piperazinyl, pyranyl, etc. Bicyclic or polycyclic heterocyclyls include spirocyclic, condensed and bridged heterocyclyls. Bicyclic or polycyclic "heterocyclyls" include those in which one ring is aromatic and the other rings are non-aromatic, including spirocyclic, condensed and bridged heterocyclyls. The heterocyclyl group may be a monocyclic (monocyclic heterocyclyl) ring system, or a fused (fused heterocyclyl or heterofused), bridged (heterobridged heterocyclyl or bridged heterocyclyl) or spiro (heterospiro or spiroheterocyclyl) ring system, such as a bicyclic system (bicyclic heterocyclyl), and may be saturated or partially unsaturated. The bicyclic heterocyclyl may contain one or more heteroatoms in one or both rings. In some embodiments, the heterocyclyl group also includes a ring system in which the heterocyclyl group as defined above is fused to one or more carbocyclyl groups, wherein the point of attachment is on the carbocyclyl or heterocyclyl ring; or, in some embodiments, the heterocyclyl group also includes a ring system in which the heterocyclyl group as defined above is fused to one or more aryl / heteroaryl groups, wherein the point of attachment is on the aryl / heteroaryl or heterocyclyl ring; or, in some embodiments, a ring system in which the heterocyclyl group as defined above is fused to one or more heterocyclyl groups as defined above, wherein the point of attachment is on either heterocyclyl ring. In the above case, the number of members of the heterocyclyl ring system is the number of ring atoms in the ring system after fusion. In some embodiments, the heterocyclyl is optionally substituted, for example, unsubstituted (unsubstituted heterocyclyl) or substituted with one or more substituents (substituted heterocyclyl). Exemplary 3-membered heterocyclyls containing 1 heteroatom include, but are not limited to, aziridinyl, oxiranyl, and thiorenyl. Exemplary 4-membered heterocyclyls containing 1 heteroatom include, but are not limited to, azetidinyl, oxitanyl, and thiidine. Exemplary 5-membered heterocyclyls containing 1 heteroatom include, but are not limited to, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, dihydrothienyl, pyrrolidinyl, dihydropyrrolyl, and 2,5-dioxopyrrolidinyl. Exemplary 5-membered heterocyclyls containing 2 heteroatoms include, but are not limited to, dioxolanyl, oxathiolanyl, dithiolanyl, and 2-oxoxazolidinyl. Exemplary 5-membered heterocyclyls containing 3 heteroatoms include, but are not limited to, triazolinyl, oxadiazolinyl, and thiadiazolinyl. Exemplary 6-membered heterocyclyls containing 1 heteroatom include, but are not limited to, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and tetrahydrothiopyranyl (thianyl).Exemplary 6-membered heterocyclic groups containing 2 heteroatoms include, but are not limited to, piperazinyl, morpholinyl, dithianyl, and dioxanyl. Exemplary 6-membered heterocyclic groups containing 3 heteroatoms include, but are not limited to, triazinanyl, oxadiazinanyl, thiadiazinanyl, oxathiazinanyl, and dioxazinanyl. Exemplary 7-membered heterocyclic groups containing 1 heteroatom include, but are not limited to, azepanyl, oxepanyl, and thiepanyl. Exemplary 8-membered heterocyclic groups containing 1 heteroatom include, but are not limited to, azocanyl, oxepanyl, and thiepanyl. Exemplary 5-membered heterocyclyls (also referred to herein as 5,6-bicyclic heterocyclyls) fused to a C6 aryl ring include, but are not limited to, dihydroindolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolinonyl, etc. Exemplary 6-membered heterocyclyls (also referred to herein as 6,6-bicyclic heterocyclyls) fused to a C6 aryl ring include, but are not limited to, tetrahydroquinolinyl, tetrahydroisoquinolinyl, etc.

[0063] The term "heteroaryl" refers to an aromatic monocyclic, bicyclic or polycyclic ring system containing 5-16 members, preferably 5-14 members, 5-12 members, 5-10 members, 5-8 members, and more preferably 5-6 members, wherein 1, 2, 3 or more ring atoms are heteroatoms and the remaining atoms are carbon, the heteroatoms are independently selected from O, N or S, and the number of heteroatoms is preferably 1, 2 or 3. Bicyclic or polycyclic heterocyclic groups include fused ring heteroaryls. Examples of heteroaryl groups include, but are not limited to, furanyl, thienyl, oxazolyl, thiazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyrrolyl, pyrazolyl, imidazolyl, triazolyl, tetrazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridazinyl, thiodiazolyl, triazinyl, phthalazinyl, quinolyl, isoquinolyl, pteridinyl, purinyl, indolyl, isoindolyl, indazolyl, benzofuranyl, benzothiophenyl, benzopyridinyl, benzopyrimidinyl, benzo pyrazinyl, benzimidazolyl, benzophthalazinyl, pyrrolo[2,3-b]pyridinyl, imidazo[1,2-a]pyridinyl, pyrazolo[1,5-a]pyridinyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-b]pyridazinyl, [1,2,4]triazolo[4,3-b]pyridazinyl, [1,2,4]triazolo[1,5-a]pyrimidinyl, [1,2,4]triazolo[1,5-a]pyridinyl, and the like.

[0064] The present invention also provides a method for preparing the above-mentioned derivative, which is prepared by the following steps, including but not limited to the following method:

[0065] Route 1: When R in the general structural formula (I) 1 Selected from R 2 , R 3 and R 4 When each is hydrogen, the preparation method of series I compounds is as follows:

[0066]

[0067] in:

[0068] Ring A, R 5 and n as described above.

[0069] The specific reaction process is as follows:

[0070] The aryl bromide raw material A undergoes Miyaura borate esterification reaction to generate the boron ester intermediate B;

[0071] The raw material 2-bromothiazole-4-carboxylic acid is subjected to Curtius rearrangement with (S)-3-aminopiperidine-1-carboxylic acid tert-butyl ester to generate (S)-3-(3-(2-bromothiazol-4-yl)ureido)piperidine-1-carboxylic acid tert-butyl ester (intermediate C-1);

[0072] The boron ester intermediate B and intermediate C-1 undergo Suzuki reaction under palladium catalysis to obtain coupling product D, and then the Boc protecting group is removed by acidification in a dichloromethane solution of trifluoroacetic acid to obtain a series of target molecules I.

[0073] Route 2: When R in the general structural formula (I) 1 Selected from R 2 and R 3 and R 4 Each is hydrogen, Ring A is selected from When n=1, the preparation method of the II series compounds is as follows:

[0074]

[0075] Where R 5 and n as described above.

[0076] The specific reaction process is as follows:

[0077] 7-Bromo-2H-benzo[b][1,4]oxazin-3(4H)-one reacts with a bromide, chloride or triflate to give intermediate E, which is then esterified with Miyaura borate to give boronate intermediate F;

[0078] The boron ester intermediate F and the thiazole urea intermediate C-1 undergo Suzuki reaction under palladium catalysis to obtain the coupling product G, and then the Boc protecting group is removed by acidification in a dichloromethane solution of trifluoroacetic acid to obtain the target molecules of series II.

[0079] Route 3: When R in the general structural formula (I) 2 , R 3 and R 4 Each is hydrogen, and ring A is R 5 for When n=1, the preparation method of III series compounds is as follows:

[0080]

[0081] in:

[0082] R 1 As mentioned before.

[0083] The specific reaction process is as follows:

[0084] The raw material 2-bromothiazole-4-carboxylic acid undergoes Curtius rearrangement and reacts with different amines to generate thiazole urea intermediate C, which then undergoes Suzuki reaction with 4-(cyclobutylmethyl)-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-benzo[b][1,4]oxazine-3(4H)-one under palladium catalysis to obtain the target molecules of series III.

[0085] Route 4: When R in the general structural formula (I) 1 Selected from R 2 and R 3 Each is hydrogen, Ring A is R 5 for When n=1, the preparation method of IV series compounds is as follows:

[0086]

[0087] in:

[0088] R 4 As mentioned before.

[0089] The specific reaction process is as follows:

[0090] The 5-substituted 2-bromothiazole-4-carboxylic acid raw material undergoes Curtius rearrangement with (S)-3-aminopiperidine-1-carboxylic acid tert-butyl ester to generate the thiazole urea intermediate H, and then 4-(cyclobutylmethyl)-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-benzo[b][1,4]oxazin-3(4H)-one undergoes Suzuki reaction under palladium catalysis to obtain the coupling product J, and finally the Boc protecting group is removed to obtain the target molecules of the IV series.

[0091] The "pharmaceutical composition" of the present invention refers to a preparation of one or more compounds of the present invention or their salts and a carrier generally accepted in the art for delivering biologically active compounds to an organism (e.g., human). The purpose of a pharmaceutical composition is to facilitate administration and delivery to an organism.

[0092] The administration routes of the compounds of the present invention or their pharmaceutically acceptable salts or their pharmaceutical compositions include, but are not limited to, oral, rectal, transmucosal, enteral administration, or topical, transdermal, inhalation, parenteral, sublingual, vaginal, intranasal, intraocular, intraperitoneal, intramuscular, subcutaneous, and intravenous administration. The preferred administration route is oral administration.

[0093] The purpose of the present invention also includes providing the use of the compound represented by formula (I) shown in the present invention, or its prodrug, tautomer, stereoisomer, solvate, isotope derivative or pharmaceutically acceptable salt in the preparation of a drug for treating diseases mediated by Polθ.

[0094] In some embodiments, the Pol θ-mediated disease is cancer or a tumor-related disease.

[0095] Furthermore, the use provided by the present invention, wherein the cancer or tumor includes solid tumors and hematological tumors; the solid tumors include breast cancer, colorectal cancer, cervical cancer, ovarian cancer, prostate cancer, gastric cancer (including gastrointestinal junction cancer), esophageal cancer, head and neck cancer, lung cancer; the hematological tumors include lymphoma and leukemia.

[0096] The purpose of the present invention also includes providing a method for preventing and / or treating diseases mediated by Polθ, which comprises administering to a patient a therapeutically effective dose of a compound represented by general formula (I), or its prodrug, tautomer, stereoisomer, solvate, isotope derivative or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of the present invention; further, the Polθ-mediated disease is cancer or a tumor-related disease; further, the use provided by the present invention, wherein the cancer or tumor comprises solid tumors and hematological tumors; the solid tumors comprise breast cancer, colorectal cancer, cervical cancer, ovarian cancer, prostate cancer, gastric cancer (including gastrointestinal junction cancer), esophageal cancer, head and neck cancer, and lung cancer; the hematological tumor comprises lymphoma and leukemia.

[0097] The compound represented by the general formula (I) of the present invention, or its prodrug, tautomer, stereoisomer, solvate, isotope derivative or pharmaceutically acceptable salt can be administered in combination with one, two or more other anticancer agents or immune checkpoint regulators for treating cancer or tumors.

[0098] Furthermore, the additional anticancer agents or immune checkpoint regulators for treating cancer or tumors include PARP inhibitors, ATR inhibitors, ATM inhibitors, WEE1 inhibitors, topoisomerase inhibitors and DNA damaging chemotherapeutic drugs.

[0099] Furthermore, the DNA damaging chemotherapy drugs include cisplatin, bleomycin, gemcitabine, and docetaxel; and the topoisomerase inhibitors include etoposide and irinotecan.

[0100] The compound represented by general formula (I) of the present invention, or its prodrug, tautomer, stereoisomer, solvate, isotope derivative or pharmaceutically acceptable salt can be used in combination with one, two or more other therapeutic methods (such as radiotherapy) for treating cancer or tumors. DETAILED DESCRIPTION

[0101] The following are specific embodiments of the present invention, which further describe the technical solution of the present invention, but the protection scope of the present invention is not limited to these embodiments. Any changes or equivalent substitutions that do not deviate from the concept of the present invention are included in the protection scope of the present invention.

[0102] Preparation of intermediates:

[0103] Intermediate A-1

[0104]

[0105] Add cesium carbonate (6.52g, 20.0mmol) and (bromomethyl)cyclobutane (2.25g, 15.0mmol) to a flask containing a mixture of 5-bromoindigo (2.26g, 10.0mmol) and N,N-dimethylformamide (20mL), and react at room temperature for 16 hours. After the reaction is completed, add water (30mL), extract with ethyl acetate (30mL*3), wash the combined organic phase with saturated sodium chloride solution (30mL), dry with anhydrous sodium sulfate, and filter. The filtrate is concentrated under reduced pressure. The residue is separated by column chromatography, the eluent polarity is 0-20% ethyl acetate: petroleum ether, and 2.2g of red oil is obtained, with a yield of 74.8%.

[0106] ESI-MS: m / z = 294.0, 296.0 [M+H] + .

[0107] Intermediates A-2 to A-4

[0108] The preparation methods of intermediates A-2 to A-4 refer to the preparation method of intermediate A-1, except that 5-bromoindigo carmine is replaced by the corresponding aryl bromide, and the other intermediate materials and preparation methods are the same as those of intermediate A-1, and the target intermediates are obtained as shown in the following table:

[0109]

[0110]

[0111] Intermediate A-5

[0112]

[0113] Step 1: Synthesis of 4-bromo-N-(cyclobutylmethyl)-2-nitroaniline

[0114] 4-Bromo-1-fluoro-2-nitrobenzene (500 mg, 2.3 mmol) was dissolved in N,N-dimethylformamide (10 mL), potassium carbonate (630 mg, 4.6 mmol) and cyclobutylmethylamine (290 mg, 3.4 mmol) were added, and the mixture was stirred at room temperature for 16 hours. The mixture was quenched with water (15 mL), extracted with ethyl acetate (10 mL*3), the combined organic phases were washed twice with 20 mL of water, dried and concentrated, and the residue was purified by column chromatography, the eluent was 18% ethyl acetate in petroleum ether solution, and 4-bromo-N-(cyclobutylmethyl)-2-nitroaniline (720 mg) was obtained as a yellow solid, with a yield of about 100.0%.

[0115] ESI-MS: m / z = 285.0, 287.0 [M+H] + .

[0116] Step 2: Synthesis of 4-bromo-N-(cyclobutylmethyl)benzene-1,2-diamine

[0117] 4-Bromo-N-(cyclobutylmethyl)-2-nitroaniline (720 mg, 2.5 mmol) was dissolved in acetic acid (10 mL) and iron powder (711 mg, 12.7 mmol) was added. The reaction was stirred at 80°C for 4 hours. The mixture was quenched with 4N sodium hydroxide (30 mL) and ethyl acetate (10 mL), and the filtrate was extracted with ethyl acetate (10 mL*3). The combined organic phases were washed twice with 20 mL of water, dried and concentrated to obtain 4-bromo-N1-(cyclobutylmethyl)benzene-1,2-diamine (540 mg) as a white solid with a yield of 83.9%.

[0118] ESI-MS: m / z = 255.0, 257.0 [M+H] + .

[0119] Step 3: Synthesis of 5-bromo-1-(cyclobutylmethyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one

[0120] 4-Bromo-N-(cyclobutylmethyl)benzene-1,2-diamine (540 mg, 2.1 mmol) was dissolved in tetrahydrofuran (10 mL), and N,N-diisopropylethylamine (824 mg, 6.4 mmol) and carbonyldiimidazole (690 mg, 4.3 mmol) were added, and the reaction was stirred at 70°C for 16 hours. The mixture was quenched with water (30 mL), filtered, and the filter cake was dried to obtain 5-bromo-1-(cyclobutylmethyl)-1,3-dihydro-2H-benzo[d]imidazole-2-one (420 mg) as a white solid with a yield of 70.6%.

[0121] ESI-MS: m / z = 281.0, 283.0 [M+H] + .

[0122] Intermediate A-6

[0123]

[0124] 5-Bromo-1-(cyclobutylmethyl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (200 mg, 0.7 mmol) was dissolved in N,N-dimethylformamide (5 mL), potassium carbonate (196 mg, 1.4 mmol) and iodomethane (150 mg, 1.1 mmol) were added at 0°C, and stirred at room temperature for 16 hours. The mixture was quenched with water (15 mL), extracted with ethyl acetate (10 mL*3), the combined organic phases were washed twice with 20 mL of water, dried and concentrated, and the residue was purified by column chromatography using petroleum ether:ethyl acetate = 82% as the eluent to obtain 5-Bromo-1-(cyclobutylmethyl)-3-methyl-1,3-dihydro-2H-benzo[d]imidazol-2-one (196 mg) as a yellow solid with a yield of 94.2%.

[0125] ESI-MS: m / z = 295.0, 297.0 [M+H] + .

[0126] Intermediate A-7

[0127]

[0128] 5-Bromo-1-(cyclobutylmethyl)indole-2,3-dione (700mg, 2.4mmol) was dissolved in dichloromethane (10mL), diethylaminosulfur trifluoride (423mg, 2.6mmol) was added, and the reaction was stirred at room temperature for 12 hours. The mixture was quenched with water (15mL), extracted with dichloromethane (10mL*3), the combined organic phases were washed twice with water (20mL each time), dried and concentrated, and the residue was purified by column chromatography, petroleum ether: ethyl acetate = 90% as eluent to obtain 5-bromo-1-(cyclobutylmethyl)-3,3-difluoroindole-2-one (594mg) as a red solid, with a yield of 79.0%.

[0129] ESI-MS: m / z = 316.0, 318.0 [M+H] + .

[0130] 1 H NMR (400MHz, DMSO-d6): δ8.00(t,J=2.0Hz,1H),7.81(d,J=8.4Hz,1H),7.30(dd,J1=8.8Hz,J2 =2.0Hz,1H),3.74(d,J=7.2Hz,2H),2.70-2.63(m,1H),1.99-1.91(m,2H),1.85-1.70(m,4H).

[0131] Intermediate A-8

[0132]

[0133] Step 1: Synthesis of tert-butyl 5-bromo-2-oxoindoline-1-carboxylate

[0134] Add di-tert-butyl dicarbonate (4.80 g, 22.0 mmol) and 4-dimethylaminopyridine (488 mg, 4.0 mmol) to a flask containing a mixture of 5-bromoindolin-2-one (4.24 g, 20.0 mmol) and dichloromethane (20 mL), and react at room temperature for 16 hours. After the reaction is completed, add water (30 mL), extract twice with dichloromethane (30 mL), wash the combined organic phase with saturated sodium chloride solution (30 mL), dry with anhydrous sodium sulfate, and filter. The filtrate is concentrated under reduced pressure, and the residue is separated by column chromatography, with an eluent polarity of 0-10% ethyl acetate: petroleum ether, to obtain 3.0 g of tert-butyl 5-bromo-2-oxoindolin-1-carboxylate as a yellow solid, with a yield of 48.1%.

[0135] ESI-MS: m / z = 312.0, 314.0 [M+H] + .

[0136] Step 2: Synthesis of tert-butyl 5'-bromo-2'-oxospiro[cyclopropane-1,3'-indoline]-1'-carboxylate

[0137] Add 1,2-dibromoethane (2.85 g, 15.2 mmol) and cesium carbonate (8.26 g, 25.0 mmol) to a flask containing a mixture of 5-bromo-2-oxoindoline-1-carboxylic acid tert-butyl ester (1.56 g, 5.0 mmol) and dimethyl sulfoxide (20 mL), and react at room temperature for 16 hours. After the reaction, add water (30 mL), extract with ethyl acetate (30 mL*3), wash the combined organic phase with saturated sodium chloride solution (30 mL), dry with anhydrous sodium sulfate, and filter. The filtrate is concentrated under reduced pressure. The residue is separated by column chromatography, the eluent polarity is 0-10% ethyl acetate: petroleum ether, and 5'-bromo-2'-oxospiro[cyclopropane-1,3'-indoline]-1'-carboxylic acid tert-butyl ester 1.1 g is obtained as a light yellow solid, with a yield of 65.1%.

[0138] ESI-MS: m / z = 338.0, 340.0 [M+H] + .

[0139] 1 H NMR (400MHz, CDCl3): δ7.81 (d, J=8.4Hz, 1H), 7.40 (dd, J1=8.8Hz, J2=2.0Hz, 1H), 6.93(d,J=2.0Hz,1H), 1.86(q,J=4.0Hz,2H), 1.64(s,9H), 1.57(q,J=4.0Hz,2H).

[0140] Step 3: Synthesis of 5'-bromospiro[cyclopropane-1,3'-indolinyl]-2'-one

[0141] Add 5'-bromo-2'-oxospiro[cyclopropane-1,3'-indoleline]-1'-carboxylic acid tert-butyl ester (1.0 g, 3.0 mmol) and 4 mol / L dioxane hydrochloride solution (5 mL) to the flask and stir at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure to obtain 5'-bromospiro[cyclopropane-1,3'-indoleline]-2'-one (600 mg crude product) as a white solid, which was directly used in the next step with a yield of 85.3%.

[0142] ESI-MS: m / z = 238.0, 240.0 [M+H] + .

[0143] Step 4: Synthesis of 5'-bromo-1'-(cyclobutylmethyl)spiro[cyclopropane-1,3'-indolin]-2'-one (Intermediate A-8)

[0144] Cesium carbonate (2.56 g, 7.6 mmol) and bromomethylcyclobutane (751 mg, 5.0 mmol) were added to a flask containing a mixture of 5'-bromospiro[cyclopropane-1,3'-indolin]-2'-one (600 mg, 2.5 mmol) and N,N-dimethylformamide (10 mL), and the mixture was reacted at room temperature for 16 hours. After the reaction, water (30 mL) was added, and the mixture was extracted with ethyl acetate (30 mL*3). The combined organic phase was washed with a saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was separated by column chromatography, with an eluent polarity of 0-10% ethyl acetate: petroleum ether to obtain 5'-bromo-1'-(cyclobutylmethyl)spiro[cyclopropane-1,3'-indolin]-2'-one (650 mg) as a red oil with a yield of 74.8%.

[0145] ESI-MS: m / z=306.0,308.0[M+H] + .

[0146] Intermediate A-9-A-12

[0147] The preparation methods of intermediates A-9 to A-12 refer to the preparation method of intermediate A-1, except that 5-bromoindigo carmine is replaced by the corresponding aryl bromide, and the other intermediate materials and preparation methods are the same as those of intermediate A-1, and the target intermediates are obtained as shown in the following table:

[0148]

[0149]

[0150] Intermediate A-13

[0151]

[0152] Step 1: Synthesis of (5-bromo-2-nitrophenyl)glycine ethyl ester

[0153] Potassium carbonate (2.76 g, 20.0 mmol) and glycine ethyl ester hydrochloride (1.40 g, 10.0 mmol) were added to a flask containing a mixture of 4-bromo-2-fluoro-1-nitrobenzene (1.06 g, 5.0 mmol) and N,N-dimethylformamide (20 mL), and the mixture was reacted at 80°C for 3 hours. After the reaction, water (30 mL) was added, and the mixture was extracted with ethyl acetate (30 mL*3). The combined organic phase was washed with a saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The crude product was separated by column chromatography, and the eluent polarity was 0-20% ethyl acetate: petroleum ether to obtain 1.10 g (5-bromo-2-nitrophenyl) glycine ethyl ester as a red oil with a yield of 73.3%.

[0154] ESI-MS: m / z = 303.0, 305.0 [M+H] + .

[0155] 1 H NMR (400 MHz, DMSO-d6): δ8.44 (t, J = 6.0 Hz, 1H), 8.02 (d, J = 8.8 Hz, 1H), 7.19 (d, J = 2.0 Hz, 1H), 6.91 (dd, J1 = 9.2 Hz, J1 = 2.0 Hz, 1H), 4.31 (d, J = 5.6 Hz, 2H), 4.21 (q, J = 7.2 Hz, 2H), 1.25 (t, J = 7.2 Hz, 3H); Step 2: Synthesis of 6-bromo-3,4-dihydroquinoxaline-2(1H)-one

[0156] Add (5-bromo-2-nitrophenyl)glycine ethyl ester (1.10 g, 3.6 mmol) and reduced iron powder (1.01 g, 18.2 mmol) to a flask, add glacial acetic acid (15 mL), and react at 70°C for 2 hours. Add 4M sodium hydroxide (30 mL) and ethyl acetate (10 mL) to the mixture, quench and filter, extract the filtrate with ethyl acetate (10 mL*3), wash the combined organic phases with 20 mL of water twice, dry and concentrate to obtain 6-bromo-3,4-dihydroquinoxaline-2(1H)-one (700 mg) as a yellow solid with a yield of 85.0%.

[0157] ESI-MS: m / z = 227.0, 229.0 [M+H] + .

[0158] 1 H NMR (400MHz, DMSO-d6): δ10.34 (s, 1H), 6.80 (d, J = 2.0Hz, 1H), 6.72 (dd, J1 = 8. 0Hz, J1 = 2.0Hz, 1H), 6.65 (d, J = 8.4Hz, 1H), 6.21 (s, 1H), 3.75 (d, J = 1.6Hz, 2H).

[0159] Step 3: Synthesis of 6-bromoquinoxaline-2(1H)-one

[0160] 6-bromo-3,4-dihydroquinoxaline-2(1H)-one (700mg, 3.1mmol), methanol (10mL), hydrogen peroxide (30%wt, 698.3mg, 6.2mmol) and sodium hydroxide (616.0mg, 15.4mmol) were added to a flask and stirred at 60°C for 5 hours. The reaction solution was cooled and concentrated, extracted with ethyl acetate (15mL), washed with water (15mL*2), the organic phase was dried and concentrated, and the crude product was separated by column chromatography, with an eluent of 0-20% ethyl acetate: petroleum ether, to obtain 6-bromoquinoxaline-2(1H)-one (600mg), with a yield of 85.7%.

[0161] ESI-MS: m / z = 225.0, 227.0 [M+H] + .

[0162] 1 H NMR (400MHz, DMSO-d6): δ12.42(s,1H),8.20(s,1H),7.97(d,J=1.6Hz,1H),7.72(dd,J1=5.6Hz,J1=1.6Hz,1H),7.27(d,J=5.6Hz,1H).

[0163] Step 4: Synthesis of 6-bromo-1-(cyclobutylmethyl)quinoxaline-2(1H)-one (Intermediate A-13)

[0164] Add 6-bromoquinoxaline-2(1H)-one (300mg, 1.3mmol), DMF (5mL), cesium carbonate (1.30g, 4.0mmol) and bromomethylcyclobutane (396.4mg, 2.7mmol) to a flask, heat to 60℃ and stir for 3 hours. The reaction solution is cooled to room temperature, extracted with ethyl acetate (15mL), washed with water (15mL*2), the combined organic phase is washed with saturated sodium chloride solution (10mL), dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure. The crude product is separated by column chromatography, eluent 0-10% ethyl acetate: petroleum ether, to obtain 6-bromo-1-(cyclobutylmethyl)quinoxaline-2(1H)-one (220mg) as a yellow solid, with a yield of 56.6%.

[0165] ESI-MS: m / z = 293.0, 295.0 [M+H] + .

[0166] 1H NMR (400MHz, DMSO-d6): δ8.28(s,1H),8.02(d,J=2.0Hz,1H),7.80(dd,J1=9.2Hz,J1=1.6Hz,1H),7. 64(d,J=9.2Hz,1H), 4.30(d,J=7.2Hz,2H), 2.78-2.68(m,1H), 1.97-1.89(m,2H), 1.88-1.74(m,4H).

[0167] Intermediate A-14

[0168]

[0169] Step 1: Synthesis of 7-bromo-2H-benzo[b][1,4]oxazin-3(4H)-one

[0170] 2-Amino-5-bromophenol (1.0 g, 5.4 mmol) was dissolved in acetonitrile (15 mL), potassium carbonate (2.2 g, 16.0 mmol) was added, chloroacetyl chloride (719 mg, 6.4 mmol) was added dropwise, the system was replaced with N2 atmosphere, and the reaction was carried out at room temperature overnight for 16 hours. After the reaction was completed, water (10 mL) was added to quench the reaction solution, and it was extracted with ethyl acetate (30 mL*3), and the combined organic phase was washed with saturated sodium chloride solution (30 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain 7-bromo-2H-benzo[b][1,4]oxazine-3(4H)-one (1.0 g), which was a colorless liquid with a yield of 82.3%.

[0171] ESI-MS: m / z = 228.0, 230.0 [M+H] + .

[0172] Step 2: Synthesis of 7-bromo-4-(cyclobutylmethyl)-2H-benzo[b][1,4]oxazin-3(4H)-one (Intermediate A-14)

[0173] 7-Bromo-2H-benzo[b][1,4]oxazine-3(4H)-one (300 mg, 1.3 mmol) was added to the reaction bottle, 5 mL of N,N-dimethylformamide was added to the system to dissolve the raw materials, cesium carbonate (1.14 g, 4.6 mmol) and bromomethylcyclobutane (242 mg, 1.6 mmol) were added, and the reaction was carried out at room temperature for 16 hours. After the reaction was completed, water (10 mL) and ethyl acetate (50 mL*3) were extracted, and the combined organic phase was washed with saturated brine (50 mL*2), dried over sodium sulfate, filtered, and the filtrate was dried and concentrated to obtain 7-bromo-4-(cyclobutylmethyl)-2H-benzo[b][1,4]oxazine-3(4H)-one (274 mg) as a yellow solid with a yield of 74.4%.

[0174] ESI-MS: m / z = 296.0, 298.0 [M+H] + .

[0175] 1 H NMR(400MHz,DMSO-d6):7.20-7.18(m,2H),7.15-7.12(m,1H),4.65(s,2H),3. 98(d,J=7.6Hz,2H),2.62-2.54(m,1H),1.93-1.87(m,2H),1.81-1.70(m,4H).

[0176] Intermediate A-15

[0177]

[0178] Step 1: Synthesis of 5-bromo-2-((cyclobutylmethyl)amino)benzamide

[0179] 2-Amino-5-bromobenzamide (2.0 g, 10.0 mmol) was dissolved in N,N-dimethylformamide (10 mL), cesium carbonate (8.15 g, 25.0 mmol) and bromomethylcyclobutane (3.33 g, 15.0 mmol) were added, the system was replaced with N2, and the reaction was carried out at 60°C for 16 h. After the reaction was completed, water (10 mL) was added to quench, and ethyl acetate (50 mL*3) was used for extraction. The organic phase was washed with saturated brine (50 mL*2), the organic phases were combined, dried and concentrated, and the residue was separated by column chromatography. The eluent was 0-25% ethyl acetate in petroleum ether solution to obtain 5-bromo-2-((cyclobutylmethyl)amino)benzamide (600 mg) as a white solid with a yield of 21.5%.

[0180] ESI-MS: m / z = 283.0, 285.0 [M+H] + .

[0181] Step 2: Synthesis of 2-(aminomethyl)-4-bromo-N-(cyclobutylmethyl)aniline

[0182] 5-Bromo-2-((cyclobutylmethyl)amino)benzamide (400mg, 1.4mmol) was dissolved in 10mL THF, cooled to 0℃, replaced with N2 environment, slowly added borane dimethyl sulfide solution (5.68mL, 5.7mmol), and reacted at 60℃ for 16h. After the reaction, it was cooled to 0℃, and methanol was slowly added to quench the reaction. Water and ethyl acetate were added to extract the reaction solution to obtain an organic phase, which was dried and concentrated. The residue was separated by column chromatography, and the eluent was 0-50% ethyl acetate in petroleum ether solution (3% triethylamine) to obtain the intermediate 2-(aminomethyl)-4-bromo-N-(cyclobutylmethyl)aniline (203mg) as a white solid with a yield of 52.6%.

[0183] ESI-MS: m / z = 269.0, 271.0 [M+H] + .

[0184] Step 3: Synthesis of 6-bromo-1-(cyclobutylmethyl)-3,4-dihydroquinazolin-2(1H)-one (Intermediate A-15)

[0185] 2-(Aminomethyl)-4-bromo-N-(cyclobutylmethyl)aniline (200 mg, 0.75 mmol) was dissolved in tetrahydrofuran (5 mL), N,N'-carbonyldiimidazole (182 mg, 1.1 mmol) and triethylamine (151.2 mg, 1.5 mmol) were added, the replacement system was N2 atmosphere, and the reaction was started at 70°C for 16 hours. After the reaction was completed, it was dried and concentrated, and the residue was separated by column chromatography, and the eluent was 0-25% ethyl acetate in petroleum ether solution to obtain 100 mg of intermediate A-15 as a white solid with a yield of 45.8%.

[0186] ESI-MS: m / z = 295.0, 297.0 [M+H] + .

[0187] Intermediate A-16

[0188]

[0189] Dissolve 5-bromo-1H-indole (1.95 g, 10.0 mmol) in N,N-dimethylformamide (20 mL), add sodium hydride (800 mg, 20.0 mmol) and (bromomethyl)cyclobutane (2.25 g, 15.0 mmol), and react at room temperature for 16 hours. After the reaction, add saturated aqueous ammonium chloride solution (30 mL), extract with ethyl acetate (30 mL*3), wash the combined organic phase with water (30 mL) and saturated sodium chloride solution (30 mL) in turn, dry over anhydrous sodium sulfate, and filter. The filtrate is concentrated under reduced pressure. The residue is separated by column chromatography, the eluent polarity is 0-20% ethyl acetate: petroleum ether, and 1.8 g of red oil is obtained, with a yield of 68.4%.

[0190] ESI-MS: m / z = 264.0, 266.0 [M+H] + .

[0191] Intermediate A-17~A-19

[0192] The preparation methods of intermediates A-17 to A-19 refer to the preparation method of intermediate A-16, except that 5-bromo-1H-indole is replaced by 5-bromo-1H-indazole, 5-bromo-1H-benzo[d]imidazole and 5-bromo-1H-pyrrolo[2,3-b]pyridine, respectively. The other intermediate materials and preparation methods are the same as those of intermediate A-16, and the target intermediates are obtained as shown in the following table:

[0193]

[0194] Intermediate C-1

[0195]

[0196] Dissolve 2-bromothiazole-4-carboxylic acid (3g, 14.4mmol) in toluene (20mL), add DPPA (5.95g, 14.4mmol) and triethylamine (4.38g, 43.3mmol), replace nitrogen, stir the system at room temperature for 4h, then heat to 120℃ and react for 45min, cool to room temperature, add (S)-3-aminopiperidine-1-carboxylic acid tert-butyl ester (2.16g, 10.8mmol), stir at room temperature and react for 4h. Add 30mL of water to the reaction solution, extract with ethyl acetate (25mL*2), combine the organic phases, dry and concentrate, and separate the residue by column chromatography, with the eluent being 0-30% ethyl acetate: petroleum ether, to obtain 2.22g of white solid, with a yield of 60.9%.

[0197] ESI-MS: m / z = 405.0 [M+H] + .

[0198] 1H NMR (400MHz, DMSO-d6): δ9.26 (s, 1H), 7.17 (s, 1H), 6.37 (d, J = 7.2Hz, 1H), 3.55 (s,1H),3.33-3.22(m,4H),1.79-1.77(m,1H),1.61(s,1H),1.43-1.30(m,11H).

[0199] Intermediates C-2~C-13

[0200] The preparation methods of intermediates C-2 to C-13 refer to the preparation method of intermediate C-1, except that (S)-3-aminopiperidine-1-carboxylic acid tert-butyl ester is replaced by the corresponding amine. The other intermediate materials and preparation methods are the same as those of intermediate C-1, and the target intermediates are obtained as shown in the following table:

[0201]

[0202] Intermediate E-1

[0203]

[0204] Dissolve 7-bromo-2H-benzo[b][1,4]oxazine-3(4H)-one (2.27g, 10.0mmol) in N,N-dimethylformamide (20mL), add cesium carbonate (6.52g, 20.0mmol) and 1-bromo-2-methylpropane (2.04g, 15.0mmol), and react at room temperature for 16 hours. After the reaction, add saturated aqueous ammonium chloride solution (30mL), extract with ethyl acetate (30mL*3), wash the combined organic phase with water (30mL) and saturated sodium chloride solution (30mL) in turn, dry over anhydrous sodium sulfate, and filter. The filtrate is concentrated under reduced pressure. The residue is separated by column chromatography, the eluent polarity is 0-20% ethyl acetate: petroleum ether, and 2.11g of colorless oil is obtained, with a yield of 74.7%.

[0205] ESI-MS: m / z = 284.0, 286.0 [M+H] + .

[0206] Intermediate E-2

[0207]

[0208] Dissolve 7-bromo-2H-benzo[b][1,4]oxazine-3(4H)-one (908mg, 4.0mmol) in N,N-dimethylformamide (10mL), add cesium carbonate (2.61g, 8.0mmol) and 2,2-dimethyloxirane (1.44g, 20.0mmol), and heat to 60℃ for 10 hours. After the reaction, add saturated aqueous ammonium chloride solution (30mL), extract with ethyl acetate (30mL*3), wash the combined organic phase with water (30mL) and saturated sodium chloride solution (30mL) in turn, dry over anhydrous sodium sulfate, and filter. The filtrate is concentrated under reduced pressure. The residue is separated by column chromatography, and the eluent polarity is 0-20% ethyl acetate: petroleum ether to obtain 832mg colorless oil with a yield of 69.6%.

[0209] ESI-MS: m / z = 300.0, 302.0 [M+H] + .

[0210] Intermediate E-3~E-15

[0211] The preparation method of intermediates E-3 to E15 refers to the preparation method of intermediate E-1, only bromomethylcyclopropane is replaced by the corresponding bromide, chloride or triflate raw material, and the other intermediate materials and preparation methods are the same as the preparation of intermediate E-1, and the target intermediates are obtained as shown in the following table:

[0212]

[0213]

[0214] Example 1. Preparation of (S)-1-(2-(1-(cyclobutylmethyl)-2,3-dioxoindolyl-5-yl)thiazol-4-yl)-3-(piperidin-3-yl)urea (target compound I-1) and its formate

[0215]

[0216] Step 1: Synthesis of 1-(cyclobutylmethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indoline-2,3-dione (Intermediate B-1)

[0217] Add intermediate A-1 (294 mg, 1.00 mmol), biboronic acid pinacol ester (305 mg, 1.20 mmol), [1,1'-bis(diphenylphosphino)ferrocene] palladium dichloride (73 mg, 0.10 mmol) and potassium acetate (300 mg, 3.00 mmol) to the flask, replace nitrogen three times, add dioxane (5 mL), and react at 100 ° C for 2 hours. After the reaction solution is cooled, add 5 mL of water, extract with ethyl acetate (5 mL*3), combine the organic phases, dry and concentrate, and separate the residue by column chromatography, eluent 0-20% ethyl acetate: petroleum ether, to obtain 301 mg of red solid, yield 87.8%.

[0218] ESI-MS: m / z = 342.0 [M+H] + .

[0219] Step 2: Synthesis of (S)-tert-butyl 3-(3-(2-(1-(cyclobutylmethyl)-2,3-dioxoindole-5-yl)thiazol-4-yl)ureido)piperidine-1-carboxylate (Intermediate D-1)

[0220] Add intermediate B-1 (68 mg, 0.20 mmol), intermediate C-1 (72.8 mg, 0.26 mmol), [1,1'-bis(diphenylphosphino)ferrocene] palladium dichloride (14 mg, 0.02 mmol) and potassium carbonate (83 mg, 0.60 mmol) to the flask in sequence, replace nitrogen three times, add dioxane (5 mL) and water (1 mL), and react at 100 ° C for 3 hours. After the reaction solution is cooled, water (5 mL) is added, extracted with ethyl acetate (5 mL*3), the organic phases are combined, dried and concentrated, and the residue is separated by column chromatography, the eluent is 0-20% ethyl acetate: petroleum ether, and 70 mg of red oil is obtained, with a yield of 64.8%.

[0221] ESI-MS: m / z = 540.0 [M + H] + .

[0222] Step 3: Synthesis of (S)-1-(2-(1-(cyclobutylmethyl)-2,3-dioxoindol-5-yl)thiazol-4-yl)-3-(piperidin-3-yl)urea (target compound I-1)

[0223] Dissolve the intermediate D-1 (32 mg, 0.06 mmol) in dioxane (2 mL), add 4N hydrogen chloride dioxane solution (2 mL), and stir at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure, extracted with saturated sodium carbonate (5 mL) and dichloromethane (5 mL*3), combined organic phases, washed with saturated brine (5 mL), and concentrated under reduced pressure to obtain 22 mg of crude product of the target compound I-1, with a yield of 84.6%.

[0224] ESI-MS: m / z = 440.0 [M + H] + .

[0225] Step 4: Preparation of formate salt of (S)-1-(2-(1-(cyclobutylmethyl)-2,3-dioxoindoline-5-yl)thiazol-4-yl)-3-(piperidin-3-yl)urea (formate salt of target compound I-1)

[0226] The crude product obtained in step 3 was separated by fully preparative liquid chromatography (column: Shim-pack GIST C18 5μm*20*250mm; mobile phase: A: water (0.1% formic acid v / v), B: acetonitrile; B%: 10%-100%, 20min) to obtain 17 mg of the formate salt of the target compound I-1 as a white solid.

[0227] ESI-MS: m / z = 440.0 [M + H] + .

[0228] Example 2, Preparation of (S)-1-(2-(1-(cyclobutylmethyl)-2-oxoindoline-5-yl)thiazol-4-yl)-3-(piperidin-3-yl)urea (target compound I-2) and its formate

[0229]

[0230] Step 1: Synthesis of (S)-tert-butyl 3-(3-(2-(1-(cyclobutylmethyl)-2-oxoindole-5-yl)thiazol-4-yl)ureido)piperidine-1-carboxylate (Intermediate I-2-pro1)

[0231] Add intermediate D-1 (70 mg, 0.13 mmol), hydrazine hydrate (5 mL) and dimethyl sulfoxide (5 mL) to the flask, heat to 100 ° C and stir for 3 hours. The reaction solution was cooled to room temperature, extracted with ethyl acetate (15 mL), washed with water (15 mL*2), the combined organic phase was washed with saturated sodium chloride solution (10 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by preparative thin layer chromatography, petroleum ether: ethyl acetate = 5:1 to obtain 32 mg of intermediate I-2-pro1 as a white solid with a yield of 46.9%.

[0232] ESI-MS: m / z = 526.0 [M+H] + .

[0233] Step 2: Synthesis of (S)-1-(2-(1-(cyclobutylmethyl)-2-oxoindoline-5-yl)thiazol-4-yl)-3-(piperidin-3-yl)urea (target compound I-2)

[0234] The intermediate I-2-pro1 (32 mg, 0.061 mmol) was dissolved in dioxane (2 mL), and 4N hydrogen chloride dioxane solution (2 mL) was added, and stirred at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure, and saturated sodium carbonate (5 mL) and dichloromethane (5 mL*3) were added for extraction. The organic phases were combined, washed with saturated brine (5 mL), and concentrated under reduced pressure to obtain 24 mg of the crude product of the target compound I-2, with a yield of 92.3%.

[0235] ESI-MS: m / z = 426.0 [M + H] + .

[0236] Step 3: Preparation of formate salt of (S)-1-(2-(1-(cyclobutylmethyl)-2-oxoindolin-5-yl)thiazol-4-yl)-3-(piperidin-3-yl)urea (formate salt of target compound I-2)

[0237] The crude product obtained in step 2 was separated by fully preparative liquid chromatography (column: Shim-pack GIST C18 5μm*20*250mm; mobile phase: A: water (0.1% formic acid v / v), B: acetonitrile; B%: 10%-100%, 20min) to obtain 14 mg of the formate salt of the target compound I-2 as a white solid.

[0238] ESI-MS: m / z = 426.0 [M + H] + .

[0239] 1 H NMR (400MHz, DMSO-d6): δ9.30(s,1H),8.31(s,1H),7.80-7.76(m,2H),7.13(d,J=8.4Hz,1H),7.05(s,1H),6.80(s,1H),3.74(d,J=7.2 Hz,2H),3.67(s,2H),3.00(d,J=11.6Hz,2H),2.78(s,1H),2.72-2.63(m,3H),1.96-1.92(m,2H),1.84-1.65(m,6H),1.49-1.29(m,3H).

[0240] Example 3. Preparation of (S)-1-(2-(1-(cyclobutylmethyl)indol-5-yl)thiazol-4-yl)-3-(piperidin-3-yl)urea (target compound I-3) and its formate

[0241]

[0242] Step 1: Synthesis of (S)-1-(2-(1-(cyclobutylmethyl)indol-5-yl)thiazol-4-yl)-3-(piperidin-3-yl)urea (target compound I-3)

[0243] Compound I-2 (50 mg, 0.12 mmol) was dissolved in anhydrous tetrahydrofuran (3 mL), nitrogen was replaced in the system, 1 mmol / L borane tetrahydrofuran solution (0.47 mL) was slowly added dropwise under ice bath, and the temperature was raised to 50°C for reaction for 6 h. Methanol was slowly added dropwise to the reaction solution to quench the reaction, and the solution was concentrated under reduced pressure, and water (5 mL) and dichloromethane (5 mL*3) were added for extraction, the organic phases were combined, washed with saturated brine (5 mL), and concentrated under reduced pressure to obtain 31 mg of crude product of target compound I-3, with a yield of 64.1%.

[0244] ESI-MS: m / z = 412.0 [M + H] + .

[0245] Step 2: Preparation of formate salt of (S)-1-(2-(1-(cyclobutylmethyl)indol-5-yl)thiazol-4-yl)-3-(piperidin-3-yl)urea (formate salt of target compound I-3)

[0246] The crude product obtained in step 1 was separated by fully preparative liquid chromatography (column: Shim-pack GIST C18 5μm*20*250mm; mobile phase: A: water (0.1% formic acid v / v), B: acetonitrile; B%: 10%-100%, 20min) to obtain 24 mg of the formate salt of the target compound I-3 as a white solid.

[0247] ESI-MS: m / z = 412.0 [M + H] + .

[0248] Example 4. Preparation of (S)-1-(2-(2-(cyclobutylmethyl)-1-oxoisoindolin-5-yl)thiazol-4-yl)-3-(piperidin-3-yl)urea (target compound I-4) and its formate

[0249]

[0250] The preparation method of the target compound I-4 refers to the preparation method of I-1 in Example 1, except that the intermediate A-1 is replaced by A-2. The other intermediate materials and preparation method are the same as steps 1 to 3 of the preparation method of I-1 in Example 1 to obtain a crude product of the target compound I-4.

[0251] ESI-MS: m / z = 426.0 [M + H] + .

[0252] The same method for preparing the formate salt of compound I-4 is based on step 4 of I-1 in Example 1. The crude I-4 obtained is separated by fully preparative liquid chromatography (column: Shim-pack GIST C18 5μm*20*250mm; mobile phase: A: water (0.1% formic acid v / v), B: acetonitrile; B%: 10%-100%, 20min) to obtain the formate salt of the target compound I-4 as a white solid. The total yield of the formate salt of I-4 prepared from D-2 in two steps is 47.3%.

[0253] ESI-MS: m / z = 426.0 [M + H] + .

[0254] 1 H NMR (400MHz, DMSO-d6): δ9.54(s,1H),8.35(s,1H),8.07(s,1H),7.99(d,J= 8.0Hz,1H),7.76(d,J=8.0Hz,1H),7.27(s,1H),7.06(s,1H),4.51(s,2H),3. 57(d,J=7.2Hz,3H),3.09(s,1H),2.90(s,1H),2.73-2.61(m,3H),2.06-2.00 (m,2H),1.91-1.74(m,6H),1.56(d,J=6.8Hz,1H),1.45(s,1H),1.24(s,1H).

[0255] Example 5. Preparation of (S)-1-(2-(2-(cyclobutylmethyl)-1,3-dioxoisoindolin-5-yl)thiazol-4-yl)-3-(piperidin-3-yl)urea (target compound I-5) and its formate

[0256]

[0257] The preparation method of the target compound I-5 refers to the preparation method of I-1 in Example 1, except that the intermediate A-1 is replaced by A-3. The other intermediate materials and preparation method are the same as steps 1 to 3 of the preparation method of I-1 in Example 1 to obtain a crude product of the target compound I-5.

[0258] ESI-MS: m / z = 440.0 [M + H] + .

[0259] The same preparation method of compound I-5 formate salt is referred to step 4 of I-1 in Example 1, and the obtained I-5 crude product is separated by full preparative liquid chromatography (column: Shim-pack GIST C18 5μm*20*250mm; mobile phase: A: water (0.1% formic acid v / v), B: acetonitrile; B%: 10%-100%, 20min) to obtain the formate salt of the target compound I-5 as a white solid, wherein the total yield of the formate salt of I-5 prepared by D-3 in two steps is 55.8%.

[0260] ESI-MS: m / z = 440.0 [M + H] + .

[0261] 1 H NMR (400MHz, DMSO-d6): δ9.64(s,1H),8.36(s,1H),8.29(d,J=5.2Hz,1H),8.23(s,1 H),7.96(d,J=5.2Hz,1H),7.35(s,1H),7.08(s,1H),3.76-3.71(m,1H),3.63(d,J=4 .8Hz,2H),3.07-3.05(m,1H),2.88-2.85(m,1H),2.73(t,J=8.4Hz,1H),2.66-2.58( m,2H),1.99-1.94(m,2H),1.83-1.70(m,6H),1.55-1.44(m,2H),1.25-1.23(m,1H).

[0262] Example 6. Preparation of (S)-1-(2-(2-(cyclobutylmethyl)isoindolin-5-yl)thiazol-4-yl)-3-(piperidin-3-yl)urea (target compound I-6) and its formate

[0263]

[0264] The preparation method of the target compound I-6 refers to the preparation method of I-3 in Example 3, except that I-2 is replaced by I-5, and the other intermediate materials and preparation method are the same as step 1 of the preparation method of Example 3 to obtain a crude product of the target compound I-6.

[0265] ESI-MS: m / z = 412.0 [M + H] + .

[0266] The same method for preparing the formate salt of compound I-6 is similar to step 2 of I-3 in Example 3. The crude I-6 obtained is separated by fully preparative liquid chromatography (column: Shim-pack GIST C18 5μm*20*250mm; mobile phase: A: water (0.1% formic acid v / v), B: acetonitrile; B%: 10%-100%, 20min) to obtain the diformic acid salt of the target compound I-6 as a white solid. The total yield of the reaction is 55.8%.

[0267] ESI-MS: m / z = 412.0 [M + H] + .

[0268] Example 7, Preparation of (S)-1-(2-(3-(cyclobutylmethyl)-2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)thiazol-4-yl)-3-(piperidin-3-yl)urea (target compound I-7) and its formate

[0269]

[0270] The preparation method of the target compound I-7 refers to the preparation method of I-1 in Example 1, except that the intermediate A-1 is replaced by A-4. The other intermediate materials and preparation method are the same as steps 1 to 3 of the preparation method of I-1 in Example 1 to obtain a crude product of the target compound I-7.

[0271] ESI-MS: m / z = 428.0 [M+H] + .

[0272] The same method for preparing the formate salt of compound I-7 is referred to step 4 in Example 1, and the crude I-7 obtained is separated by a fully preparative liquid chromatograph (column: Shim-pack GIST C18 5μm*20*250mm; mobile phase: A: water (0.1% formic acid v / v), B: acetonitrile; B%: 10%-100%, 20min) to obtain the formate salt of the target compound I-7 as a white solid, wherein the total yield of the formate salt of I-7 prepared from D-4 in two steps is 72.1%.

[0273] ESI-MS: m / z = 428.0 [M+H] + .

[0274] Example 8, Preparation of (S)-1-(2-(1-(cyclobutylmethyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)thiazol-4-yl)-3-(piperidin-3-yl)urea (target compound I-8) and its formate

[0275]

[0276] The preparation method of the target compound I-8 refers to the preparation method of I-1 in Example 1, except that the intermediate A-1 is replaced by A-5. The other intermediate materials and preparation method are the same as steps 1 to 3 of the preparation method of I-1 in Example 1 to obtain a crude product of the target compound I-8.

[0277] ESI-MS: m / z = 427.0 [M+H] + .

[0278] The same method for preparing the formate salt of compound I-8 is referred to step 4 in Example 1, and the obtained crude I-8 is separated by a fully preparative liquid chromatograph (column: Shim-pack GIST C18 5μm*20*250mm; mobile phase: A: water (0.1% formic acid v / v), B: acetonitrile; B%: 10%-100%, 20min) to obtain the formate salt of the target compound I-8 as a white solid, wherein the total yield of the formate salt of I-8 prepared from D-5 in two steps is 53.9%.

[0279] ESI-MS: m / z = 427.0 [M+H] + .

[0280] 1 H NMR (400MHz, DMSO-d6): δ11.13(s,1H),9.48(s,1H),8.36(s,1H),7.54(dd,J1=8 .0Hz,J1=1.2Hz,1H),7.47(s,1H),7.24(d,J=8.4Hz,1H),7.06(s,1H),7.01(s,1H ),3.85(d,J=7.2Hz,2H),3.75(s,1H),3.11(d,J=11.2Hz,1H),2.93(d,J=11.2Hz, 1H),2.76-2.60(m,3H),1.95-1.91(m,2H),1.86-1.70(m,6H),1.56-1.43(m,3H).

[0281] Example 9, Preparation of (S)-1-(2-(1-(cyclobutylmethyl)-3-methyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)thiazol-4-yl)-3-(piperidin-3-yl)urea (target compound I-9) and its formate

[0282]

[0283] The preparation method of the target compound I-9 refers to the preparation method of I-1 in Example 1, except that the intermediate A-1 is replaced by A-6. The other intermediate materials and preparation method are the same as steps 1 to 3 of the preparation method of I-1 in Example 1 to obtain a crude product of the target compound I-9.

[0284] ESI-MS: m / z = 441.0 [M+H] + .

[0285] The same method for preparing the formate salt of compound I-9 is referred to step 4 in Example 1, and the obtained crude I-9 is separated by a fully preparative liquid chromatograph (column: Shim-pack GIST C18 5μm*20*250mm; mobile phase: A: water (0.1% formic acid v / v), B: acetonitrile; B%: 10%-100%, 20min) to obtain the formate salt of the target compound I-9 as a white solid, wherein the total yield of the formate salt of I-9 prepared from D-6 in two steps is 64.2%.

[0286] ESI-MS: m / z = 441.0 [M+H] + .

[0287] 1 H NMR (400MHz, DMSO-d6): δ9.44(s,1H),8.32(s,1H),7.67-7.54(m,2H),7.30(d, J=8.2Hz,1H),7.09(s,1H),6.88(d,J=6.8Hz,1H),3.89(d,J=7.2Hz,2H),3.78-3 .70(m,1H),3.39(s,3H),3.15-3.05(m,1H),2.92-2.89(m,1H),2.79-2.66(m,2 H),2.64-2.54(m,1H),1.95-1.91(m,2H),1.86-1.69(m,6H),1.64-1.35(m,3H).

[0288] Example 10. Preparation of (S)-1-(2-(1-(cyclobutylmethyl)-3,3-difluoro-2-oxoindolyl-5-yl)thiazol-4-yl)-3-(piperidin-3-yl)urea (target compound I-10)

[0289]

[0290] The preparation method of the target compound I-10 refers to the preparation method of I-1 in Example 1, except that the intermediate A-1 is replaced by A-7. The other intermediate materials and preparation method are the same as steps 1 to 3 of the preparation method of I-1 in Example 1 to obtain a crude product of the target compound I-10.

[0291] ESI-MS: m / z = 462.0 [M+H] + .

[0292] The same method for preparing the formate salt of compound I-10 is referred to step 4 in Example 1, and the crude I-10 obtained is separated by a fully preparative liquid chromatograph (column: Shim-pack GIST C18 5μm*20*250mm; mobile phase: A: water (0.1% formic acid v / v), B: acetonitrile; B%: 10%-100%, 20min) to obtain the formate salt of the target compound I-10 as a white solid, wherein the total yield of the formate salt of I-10 prepared from D-7 in two steps is 44.8%.

[0293] ESI-MS: m / z = 462.0 [M+H] + .

[0294] 1 H NMR (400MHz, DMSO-d6): δ9.33(s,1H),8.16(d,J=2.0Hz,1H),8.11(d,J=8.8Hz,1H ),7.43(d,J=8.4Hz,1H),7.14(s,1H),6.74(s,1H),3.79(d,J=7.2Hz,2H),3.61(s, 1H),2.96-2.88(m,1H),2.75-2.67(m,2H),2.60(d,J=8.4Hz,1H),2.47-2.38(m,1H ),2.00-1.97(m,2H),1.90-1.70(m,5H),1.60(d,J=8.4Hz,2H),1.49-1.31(m,2H).

[0295] Example 11, Preparation of (S)-1-(2-(1'-(cyclobutylmethyl)-2'-oxospiro[cyclopropane-1,3'-indolin]-5'-yl)thiazol-4-yl)-3-(piperidin-3-yl)urea (target compound I-11) and its formate

[0296]

[0297] The preparation method of the target compound I-11 refers to the preparation method of I-1 in Example 1, except that the intermediate A-1 is replaced by A-8. The other intermediate materials and preparation method are the same as steps 1 to 3 of the preparation method of I-1 in Example 1 to obtain a crude product of the target compound I-11.

[0298] ESI-MS: m / z = 452.0 [M + H] + .

[0299] The same method for preparing the formate salt of compound I-11 is referred to step 4 in Example 1, and the crude I-11 obtained is separated by a fully preparative liquid chromatograph (column: Shim-pack GIST C18 5μm*20*250mm; mobile phase: A: water (0.1% formic acid v / v), B: acetonitrile; B%: 10%-100%, 20min) to obtain the formate salt of the target compound I-11 as a white solid, wherein the total yield of the formate salt of I-11 prepared from D-8 in two steps is 73.2%.

[0300] ESI-MS: m / z = 452.0 [M + H] + .

[0301] 1 H NMR (400MHz, DMSO-d6): δ9.38(s,1H),8.31(s,1H),7.77(dd,J1=8.4Hz,J2=2.0Hz,1H),7.47(d,J =1.6Hz,1H),7.22(d,J=8.4Hz,1H),7.08(s,1H),6.75(d,J=7.6Hz,1H),3.82(d,J=7.2Hz,2H),3. 73(d,J=10.0Hz,2H),3.12(dd,J1=11.6Hz,J2=4.0Hz,1H),2.94(d,J=12.0Hz,1H),2.75-2.68(m, 2H),2.63-2.58(m,1H),1.98-1.93(m,2H),1.87-1.73(m,8H),1.63-51(m,3H),1.49-1.36(m,1H).

[0302] Example 12, Preparation of (S)-1-(2-(1-(cyclobutylmethyl)-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)thiazol-4-yl)-3-(piperidin-3-yl)urea (target compound I-12) and its formate

[0303]

[0304] The preparation method of the target compound I-12 refers to the preparation method of I-1 in Example 1, except that the intermediate A-1 is replaced by A-9. The other intermediate materials and preparation method are the same as steps 1 to 3 of the preparation method of I-1 in Example 1 to obtain a crude product of the target compound I-12.

[0305] ESI-MS: m / z = 440.0 [M + H] + .

[0306] The same method for preparing the formate salt of compound I-12 is referred to step 4 in Example 1, and the obtained crude I-12 is separated by a fully preparative liquid chromatograph (column: Shim-pack GIST C18 5μm*20*250mm; mobile phase: A: water (0.1% formic acid v / v), B: acetonitrile; B%: 10%-100%, 20min) to obtain the formate salt of the target compound I-12 as a white solid, wherein the total yield of the formate salt of I-12 prepared from D-9 in two steps is 75.5%.

[0307] 1 H NMR (400MHz, DMSO-d6): δ9.43(s,1H),8.33(s,1H),7.73(dd,J1=8.4Hz,J2=2.4Hz,1H),7.70(d, J=2.0Hz,1H),7.23(d,J=8.4Hz,1H),7.11(s,1H),6.92(s,1H),4.02(d,J=7.2Hz,2H),3.74(d,J= 9.2Hz,1H),3.09(dd,J1=11.6Hz,J2=3.6Hz,1H),2.92-2.89(m,3H),2.71(t,J=10.8Hz,1H),2.6 3-2.56(m,4H),1.93-1.88(m,2H),1.82-1.70(m,7H),1.55(d,J=10.8Hz,1H),1.47-1.42(m,1H).

[0308] Example 13. Preparation of (S)-1-(2-(1-(cyclobutylmethyl)-1,2,3,4-tetrahydroquinolin-6-yl)thiazol-4-yl)-3-(piperidin-3-yl)urea (target compound I-13) and its formate

[0309]

[0310] The preparation method of the target compound I-13 refers to the preparation method of I-3 in Example 3, except that I-2 is replaced by I-12. The other intermediate materials and preparation method are the same as step 1 of the preparation method of Example 3 to obtain a crude product of the target compound I-13.

[0311] ESI-MS: m / z = 426.0 [M + H] + .

[0312] The same method for preparing the formate salt of compound I-13 is referred to step 2 of I-3 in Example 3. The crude I-13 obtained is separated by a fully preparative liquid chromatograph (column: Shim-pack GIST C18 5μm*20*250mm; mobile phase: A: water (0.1% formic acid v / v), B: acetonitrile; B%: 10%-100%, 20min) to obtain the formate salt of the target compound I-13 as a white solid. The total yield of the two-step reaction is 92.5%.

[0313] ESI-MS: m / z = 426.0 [M + H] + .

[0314] 1 H NMR (400MHz, DMSO-d6): δ9.29(s,1H),8.33(s,1H),7.46(dd,J1=8.8Hz,J2=2.8Hz,1H),7.36 (d,J=2.4Hz,1H),6.93(d,J=7.4Hz,1H),6.89(s,1H),6.60(d,J=8.8Hz,1H),3.74(d,J=9.2Hz ,1H),3.35-3.31(m,4H),3.14-3.06(m,1H),2.92(d,J=12.0Hz,1H),2.72(t,J=6.4Hz,3H),2. 67-2.59(m,2H),2.02-1.96(m,2H),1.85-1.78(m,8H),1.57-1.54(m,1H),1.49-1.36(m,2H).

[0315] Example 14. Preparation of (S)-1-(2-(2-(cyclobutylmethyl)-1-oxo-1,2,3,4-tetrahydroisoquinolin-6-yl)thiazol-4-yl)-3-(piperidin-3-yl)urea (target compound I-14) and its formate

[0316]

[0317] The preparation method of the target compound I-14 is similar to the preparation method of I-1 in Example 1, except that the intermediate A-1 is replaced by A-10. The other intermediate materials and preparation method are the same as steps 1 to 3 of the preparation method of I-1 in Example 1 to obtain a crude product of the target compound I-14.

[0318] ESI-MS: m / z = 440.0 [M + H] + .

[0319] The same method for preparing the formate salt of compound I-14 is referred to step 4 in Example 1, and the crude I-14 is separated by a fully preparative liquid chromatograph (column: Shim-pack GIST C18 5μm*20*250mm; mobile phase: A: water (0.1% formic acid v / v), B: acetonitrile; B%: 10%-100%, 20min) to obtain the formate salt of the target compound I-14 as a white solid, wherein the total yield of the formate salt of I-14 prepared from D-10 in two steps is 74.7%.

[0320] ESI-MS: m / z = 440.0 [M + H] + .

[0321] 1 H NMR (400MHz, DMSO-d6): 9.55 (s, 1H), 8.35 (s, 1H), 7.94 (d, J = 8.1Hz, 1H), 7.84 (dd, J1 = 8.0Hz, J2=2.0Hz,1H),7.77(d,J=1.6Hz,1H),7.26(s,1H),7.02(d,J=7.6Hz,1H),3.75-3.71(m,1H), 3.53(d,J=7.2Hz,4H),3.10-3.05(m,1H),3.01(t,J=6.4Hz,2H),2.88(d,J=12.4Hz,1H),2.71 (d,J=9.2Hz,1H),2.64-2.57(m,2H),2.03-1.95(m,2H),1.81-1.73(m,7H),1.55-1.42(m,2H).

[0322] Example 15. Preparation of (S)-1-(2-(2-(cyclobutylmethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl)thiazol-4-yl)-3-(piperidin-3-yl)urea (target compound I-15) and its formate

[0323]

[0324] The preparation method of the target compound I-15 refers to the preparation method of I-3 in Example 3, except that I-2 is replaced by I-14. The other intermediate materials and preparation method are the same as step 1 of the preparation method of Example 3 to obtain a crude product of the target compound I-15.

[0325] ESI-MS: m / z = 426.0 [M + H] + .

[0326] The same method for preparing the formate salt of compound I-15 is referred to step 2 of I-3 in Example 3. The crude I-15 obtained is separated by a fully preparative liquid chromatograph (column: Shim-pack GIST C18 5μm*20*250mm; mobile phase: A: water (0.1% formic acid v / v), B: acetonitrile; B%: 10%-100%, 20min) to obtain the diformic acid salt of the target compound I-15 as a white solid. The total yield of the two-step reaction is 86.6%.

[0327] ESI-MS: m / z = 426.0 [M + H] + .

[0328] Example 16, Preparation of (S)-1-(2-(2-(cyclobutylmethyl)-1,2,3,4-tetrahydroisoquinolin-7-yl)thiazol-4-yl)-3-(piperidin-3-yl)urea (target compound I-16) and its formate

[0329]

[0330] The preparation method of the target compound I-16 refers to the preparation method of I-1 in Example 1, except that the intermediate A-1 is replaced by A-11. The other intermediate materials and preparation method are the same as steps 1 to 3 of the preparation method of I-1 in Example 1 to obtain a crude product of the target compound I-16.

[0331] ESI-MS: m / z = 426.0 [M + H] + .

[0332] The same method for preparing the formate salt of compound I-16 is referred to step 4 of I-1 in Example 1, and the crude I-16 is separated by a fully preparative liquid chromatograph (column: Shim-pack GIST C18 5μm*20*250mm; mobile phase: A: water (0.1% formic acid v / v), B: acetonitrile; B%: 10%-100%, 20min) to obtain the dimethicone salt of the target compound I-16 as a white solid, wherein the total yield of the two-step reaction of the dimethicone salt of I-16 prepared from D-11 is 74.7%.

[0333] ESI-MS: m / z = 510.0 [M+H] + .

[0334] 1H NMR (400MHz, DMSO-d6): δ9.44(s,1H),8.28(s,2H),7.61(dd,J1=8.0Hz,J2=2.0Hz,1H),7.54(d,J=2.0Hz,1 H),7.19(d,J=8.0Hz,1H),7.13(s,1H),6.93(d,J=7.6Hz,1H),3.77(s,1H),3.57-3.56(m,2H),3.18-3.09(m ,2H),2.97-2.93(m,1H),2.81(t,J=5.2Hz,2H),2.76-2.71(m,1H),2.69-2.55(m,5H),2.09-2.01(dd,J1=10 .4Hz,J2=7.2Hz,2H),1.94-1.77(m,4H),1.74-1.64(m,3H),1.58(d,J=10.0Hz,1H),1.44(d,J=10.0Hz,1H).

[0335] Example 17, Preparation of (S)-1-(2-(1-(cyclobutylmethyl)-2-oxo-1,2-dihydroquinolin-6-yl)thiazol-4-yl)-3-(piperidin-3-yl)urea (target compound I-17) and its formate

[0336]

[0337] The preparation method of the target compound I-17 refers to the preparation method of I-1 in Example 1, except that the intermediate A-1 is replaced by A-12. The other intermediate materials and preparation method are the same as steps 1 to 3 of the preparation method of I-1 in Example 1 to obtain a crude product of the target compound I-17.

[0338] ESI-MS: m / z = 438.0 [M+H] + .

[0339] The same method for preparing the formate salt of compound I-17 is referred to step 4 in Example 1, and the crude I-17 obtained is separated by a fully preparative liquid chromatograph (column: Shim-pack GIST C18 5μm*20*250mm; mobile phase: A: water (0.1% formic acid v / v), B: acetonitrile; B%: 10%-100%, 20min) to obtain the formate salt of the target compound I-17 as a white solid, wherein the total yield of the formate salt of I-17 prepared from D-12 in two steps is 55.2%.

[0340] ESI-MS: m / z = 438.0 [M+H] + .

[0341] 1H NMR (400MHz, DMSO-d6): δ9.52 (s, 1H), 8.36 (s, 1H), 8.22 (d, J = 2.4Hz, 1H), 8.11-7.9 9(m,2H),7.67(d,J=9.2Hz,1H),7.19(s,1H),7.04(d,J=6.4Hz,1H),6.68(d,J=9.6Hz ,1H),4.38(d,J=7.2Hz,3H),3.77(d,J=9.6Hz,1H),3.11(dd,J1=12.0Hz,J2=4.0Hz,1 H), 2.92 (d, J = 12.4Hz, 1H), 2.79-2.61 (m, 3H), 1.99-1.73 (m, 8H), 1.62-1.41 (m, 2H).

[0342] Example 18, Preparation of (S)-1-(2-(1-(cyclobutylmethyl)-2-oxo-1,2-dihydroquinoxaline-6-yl)thiazol-4-yl)-3-(piperidin-3-yl)urea (target compound I-18) and its formate

[0343]

[0344] The preparation method of the target compound I-18 refers to the preparation method of I-1 in Example 1, except that the intermediate A-1 is replaced by A-13. The other intermediate materials and preparation method are the same as steps 1 to 3 of the preparation method of I-1 in Example 1 to obtain a crude product of the target compound I-18.

[0345] ESI-MS: m / z = 439.0 [M+H] + .

[0346] The preparation of the formate salt of the same compound I-18 can refer to step 4 in Example 1, and the obtained crude I-18 is separated by a fully preparative liquid chromatograph (column: Shim-pack GIST C18 5μm*20*250mm; mobile phase: A: water (0.1% formic acid v / v), B: acetonitrile; B%: 10%-100%, 20min) to obtain the formate salt of the target compound I-18 as a white solid, wherein the total yield of the formate salt of I-18 prepared from D-13 in two steps is 47.9%.

[0347] ESI-MS: m / z = 439.0 [M+H] + .

[0348] Example 19, Preparation of (S)-1-(2-(4-(cyclobutylmethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)thiazol-4-yl)-3-(piperidin-3-yl)urea (target compound I-19) and its formate

[0349]

[0350] The preparation method of the target compound I-19 refers to the preparation method of I-1 in Example 1, except that the intermediate A-1 is replaced by A-14. The other intermediate materials and preparation method are the same as steps 1 to 3 of the preparation method of I-1 in Example 1 to obtain a crude product of the target compound I-19.

[0351] ESI-MS: m / z = 442.0 [M + H] + .

[0352] The same method for preparing the formate salt of compound I-19 is referred to step 4 in Example 1, and the crude I-19 obtained is separated by a fully preparative liquid chromatograph (column: Shim-pack GIST C18 5μm*20*250mm; mobile phase: A: water (0.1% formic acid v / v), B: acetonitrile; B%: 10%-100%, 20min) to obtain the formate salt of the target compound I-19 as a white solid, wherein the total yield of the formate salt of I-19 prepared from D-14 in two steps is 56.1%.

[0353] ESI-MS: m / z = 442.0 [M + H] + .

[0354] 1 H NMR (400MHz, DMSO-d6): δ9.38(s,1H),8.26(s,1H),7.54(dd,J1=8.4Hz,J2=2.0Hz,1H),7.44(d ,J=2.0Hz,1H),7.31(d,J=8.8Hz,1H),7.13(s,1H),6.70(s,1H),4.71(s,2H),4.03(d,J=7.2Hz ,2H),3.66(s,2H),3.03(d,J=11.6Hz,1H),2.85(d,J=10.0Hz,1H),2.63(t,J=8.0Hz,3H),1.95 -1.90(m,2H),1.83-1.73(m,5H),1.67(s,1H),1.49(d,J=10.8Hz,1H),1.39(d,J=10.0Hz,1H).

[0355] Example 20, Preparation of (S)-1-(2-(1-(cyclobutylmethyl)-2-oxo-1,2,3,4-tetrahydroquinazolin-6-yl)thiazol-4-yl)-3-(piperidin-3-yl)urea (target compound I-20) and its formate

[0356]

[0357] The preparation method of the target compound I-20 refers to the preparation method of I-1 in Example 1, except that the intermediate A-1 is replaced by A-15. The other intermediate materials and preparation method are the same as steps 1 to 3 of the preparation method of I-1 in Example 1 to obtain a crude product of the target compound I-20.

[0358] ESI-MS: m / z = 441.0 [M+H] + .

[0359] The same method for preparing the formate salt of compound I-20 is referred to step 4 of I-1 in Example 1, and the crude I-20 obtained is separated by a fully preparative liquid chromatograph (column: Shim-pack GIST C18 5μm*20*250mm; mobile phase: A: water (0.1% formic acid v / v), B: acetonitrile; B%: 10%-100%, 20min) to obtain the formate salt of the target compound I-20 as a white solid, wherein the total yield of the formate salt of I-20 prepared from D-15 in two steps is 63.6%.

[0360] ESI-MS: m / z = 441.0 [M+H] + .

[0361] 1 H NMR (400MHz, DMSO-d6): δ9.46(s,1H),9.30(s,1H),8.36(s,1H),7.77-7.54(m,1H),7.22-6.52(m,1H),4.45(s,2H),3.64(s,2H),3.37(d,J =7.2Hz,2H),3.00(d,J=11.6Hz,1H),2.78(s,1H),2.66-2.59(m,2H),2.01-2.00(m,1H),1.86-1.64(m,7H),1.64(s,1H),1.47-1.37(m,2H).

[0362] Example 21, Preparation of (S)-1-(2-(1-(cyclobutylmethyl)-1H-indol-5-yl)thiazol-4-yl)-3-(piperidin-3-yl)urea (target compound I-21) and its formate

[0363]

[0364] The preparation method of the target compound I-21 refers to the preparation method of I-1 in Example 1, except that the intermediate A-1 is replaced by A-16. The other intermediate materials and preparation method are the same as steps 1 to 3 of the preparation method of I-1 in Example 1 to obtain a crude product of the target compound I-21.

[0365] ESI-MS: m / z = 410.0 [M + H] + .

[0366] The same method for preparing the formate salt of compound I-21 is referred to step 4 of I-1 in Example 1, and the crude I-21 obtained is separated by a fully preparative liquid chromatograph (column: Shim-pack GIST C18 5μm*20*250mm; mobile phase: A: water (0.1% formic acid v / v), B: acetonitrile; B%: 10%-100%, 20min) to obtain the formate salt of the target compound I-21 as a white solid, wherein the total yield of the formate salt of I-21 prepared from D-16 in two steps is 71.9%.

[0367] ESI-MS: m / z = 410.0 [M + H] + .

[0368] Example 22, Preparation of (S)-1-(2-(1-(cyclobutylmethyl)-1H-indazol-5-yl)thiazol-4-yl)-3-(piperidin-3-yl)urea (target compound I-22) and its formate

[0369]

[0370] The preparation method of the target compound I-22 refers to the preparation method of I-1 in Example 1, except that the intermediate A-1 is replaced by A-17. The other intermediate materials and preparation method are the same as steps 1 to 3 of the preparation method of I-1 in Example 1 to obtain a crude product of the target compound I-22.

[0371] ESI-MS: m / z = 411.0 [M+H] + .

[0372] The same method for preparing the formate salt of compound I-22 is referred to step 4 in Example 1, and the crude I-22 obtained is separated by a fully preparative liquid chromatograph (column: Shim-pack GIST C18 5μm*20*250mm; mobile phase: A: water (0.1% formic acid v / v), B: acetonitrile; B%: 10%-100%, 20min) to obtain the formate salt of the target compound I-22 as a white solid, wherein the total yield of the formate salt of I-22 prepared from D-17 in two steps is 49.8%.

[0373] ESI-MS: m / z = 411.0 [M+H] + .

[0374] 1 H NMR (400MHz, DMSO-d6): δ9.41 (s, 1H), 8.32-8.27 (m, 2H), 8.17 (s, 1H), 7.89 (dd, J1=8.8Hz, J2=1 .6Hz,1H),7.81(d,J=8.8Hz,1H),7.11(s,1H),6.85(s,1H),4.45(d,J=7.2Hz,2H),3.74(s,1H), 3.12(d,J=11.6Hz,1H),2.93(d,J=11.6Hz,1H),2.87-2.81(m,1H),2.74(d,J=10.0Hz,1H),2.62 (t,J=10.4Hz,1H),1.96-1.90(m,2H),1.87-1.71(m,7H),1.57-1.54(m,1H),1.47-1.43(m,1H).

[0375] Example 23, Preparation of (S)-1-(2-(1-(cyclobutylmethyl)-1H-benzo[d]imidazol-5-yl)thiazol-4-yl)-3-(piperidin-3-yl)urea (target compound I-23) and its formate

[0376]

[0377] The preparation method of the target compound I-23 refers to the preparation method of I-1 in Example 1, except that the intermediate A-1 is replaced by A-18. The other intermediate materials and preparation method are the same as steps 1 to 3 of the preparation method of I-1 in Example 1 to obtain a crude product of the target compound I-23.

[0378] ESI-MS: m / z = 411.0 [M+H] + .

[0379] The same method for preparing the formate salt of compound I-23 is referred to step 4 in Example 1, and the crude I-23 obtained is separated by a fully preparative liquid chromatograph (column: Shim-pack GIST C18 5μm*20*250mm; mobile phase: A: water (0.1% formic acid v / v), B: acetonitrile; B%: 10%-100%, 20min) to obtain the formate salt of the target compound I-23 as a white solid, wherein the total yield of the formate salt of I-23 prepared by D-18 in two steps is 77.0%.

[0380] ESI-MS: m / z = 411.0 [M+H]+ .

[0381] Example 24, Preparation of (S)-1-(2-(1-(cyclobutylmethyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)thiazol-4-yl)-3-(piperidin-3-yl)urea (target compound I-24) and its formate

[0382]

[0383] The preparation method of the target compound I-24 refers to the preparation method of I-1 in Example 1, except that the intermediate A-1 is replaced by A-19. The other intermediate materials and preparation method are the same as steps 1 to 3 of the preparation method of I-1 in Example 1 to obtain a crude product of the target compound I-24.

[0384] ESI-MS: m / z = 411.0 [M+H] + .

[0385] The same method for preparing the formate salt of compound I-24 is based on step 4 of I-1 in Example 1. The crude I-24 obtained is separated by fully preparative liquid chromatography (column: Shim-pack GIST C18 5μm*20*250mm; mobile phase: A: water (0.1% formic acid v / v), B: acetonitrile; B%: 10%-100%, 20min) to obtain the formate salt of the target compound I-24 as a white solid. The total yield of the formate salt of I-24 prepared from D-19 in two steps is 42.5%.

[0386] ESI-MS: m / z = 411.0 [M+H] + .

[0387] 1 H NMR (400MHz, DMSO-d6): δ9.47(s,1H),8.78(d,J=2.0Hz,1H),8.42(d,J=2.0Hz,1H),8.3 4(s,1H),7.66(d,J=3.6Hz,1H),7.14(s,1H),6.94(d,J=7.6Hz,1H),6.58(d,J=3.6Hz,1H ),4.32(d,J=7.6Hz,2H),3.76-3.72(m,1H),3.13(dd,J1=11.6Hz,J2=4.0Hz,1H),2.94-2 .78(m,2H),2.75-2.59(m,2H),1.98-1.89(m,2H),1.88-1.72(m,7H),1.59-1.40(m,2H).

[0388] Example 25. Preparation of (S)-1-(2-(4-isobutyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)thiazol-4-yl)-3-(piperidin-3-yl)urea (target compound II-1) and its formate

[0389]

[0390] Step 1: Synthesis of 4-isobutyl-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-benzo[b][1,4]oxazin-3(4H)-one (Intermediate F-1)

[0391] Add intermediate E-1 (283 mg, 1.00 mmol), biboronic acid pinacol ester (305 mg, 1.20 mmol), [1,1'-bis(diphenylphosphino)ferrocene] palladium dichloride (73 mg, 0.10 mmol) and potassium acetate (300 mg, 3.00 mmol) to the flask, replace nitrogen three times, add dioxane (5 mL), and react at 100 ° C for 2 hours. After the reaction solution is cooled, 5 mL of water is added, extracted with ethyl acetate (5 mL*3), the organic phases are combined, dried and concentrated, and the residue is separated by column chromatography, the eluent is 0-20% ethyl acetate: petroleum ether, and 310 mg of yellow solid is obtained, with a yield of 93.7%.

[0392] ESI-MS: m / z = 332.0 [M+H] + .

[0393] Step 2: Synthesis of (S)-tert-butyl 3-(3-(2-(4-isobutyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)thiazol-4-yl)ureido)piperidine-1-carboxylate (Intermediate G-1)

[0394] Add intermediate F-1 (66 mg, 0.20 mmol), intermediate C-1 (72.8 mg, 0.26 mmol), [1,1'-bis(diphenylphosphino)ferrocene] palladium dichloride (14 mg, 0.02 mmol) and potassium carbonate (83 mg, 0.60 mmol) to the flask in sequence, replace nitrogen three times, add dioxane (5 mL) and water (1 mL), and react at 100 ° C for 3 hours. After the reaction solution is cooled, add 5 mL of water, extract with ethyl acetate (5 mL*3), combine the organic phases, dry and concentrate, and separate the residue by column chromatography, eluent 0-20% ethyl acetate: petroleum ether, to obtain 78 mg of yellow solid, yield 73.6%.

[0395] ESI-MS: m / z = 530.0 [M + H] + .

[0396] Step 3: Synthesis of (S)-1-(2-(4-isobutyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)thiazol-4-yl)-3-(piperidin-3-yl)urea (target compound II-1)

[0397] Dissolve the intermediate D-1 (53 mg, 0.10 mmol) in dioxane (2 mL), add 4N hydrogen chloride dioxane solution (2 mL), and stir at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure, extracted with saturated sodium carbonate (5 mL) and dichloromethane (5 mL*3), and the organic phases were combined, washed with saturated brine (5 mL), and concentrated under reduced pressure to obtain 38 mg of the crude product of the target compound II-1, with a yield of 88.4%.

[0398] ESI-MS: m / z = 430.0 [M + H] + .

[0399] Step 4: Preparation of formate salt of (S)-1-(2-(4-isobutyl-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)thiazol-4-yl)-3-(piperidin-3-yl)urea (formate salt of target compound II-1)

[0400] The crude product from the previous step was separated by fully preparative liquid chromatography (column: Shim-pack GIST C18 5μm*20*250mm; mobile phase: A: water (0.1% formic acid v / v), B: acetonitrile; B%: 10%-100%, 20min) to obtain 21 mg of the formate salt of the target compound II-1 as a white solid.

[0401] ESI-MS: m / z = 430.0 [M + H] + .

[0402] Example 26. Preparation of target compounds II-2 to II-15 and their formate salts

[0403] The preparation methods of target compounds II-2 to II-15 are similar to those of II-1, except that intermediate E-1 is replaced by E-2 to E-15. Other intermediate materials and preparation methods are the same as those of target compound II-1, as shown in the following table:

[0404]

[0405]

[0406] Example 27, Preparation of (R)-1-(2-(4-(cyclobutylmethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)thiazol-4-yl)-3-(piperidin-3-yl)urea (target compound III-1) and its formate

[0407]

[0408] Step 1: Synthesis of tert-butyl (R)-3-(3-(2-(4-(cyclobutylmethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)thiazol-4-yl)ureido)piperidine-1-carboxylate (Intermediate III-1-pro1)

[0409] Add intermediate B-14 (68 mg, 0.20 mmol), intermediate C-2 (73 mg, 0.26 mmol), [1,1'-bis(diphenylphosphino)ferrocene] dichloropalladium (14 mg, 0.02 mmol) and potassium carbonate (83 mg, 0.60 mmol) to the flask in sequence, replace nitrogen three times, add dioxane (5 mL), water (1 mL) and react at 100 ° C for 3 hours. After the reaction solution is cooled, add 5 mL of water, extract with ethyl acetate (5 mL*3), combine the organic phases, dry and concentrate, and separate the residue by column chromatography, eluent 0-20% ethyl acetate: petroleum ether, to obtain 77 mg of red oil, yield 71.2%.

[0410] ESI-MS: m / z = 542.0 [M+H] + .

[0411] Step 2: Synthesis of (R)-1-(2-(4-(cyclobutylmethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)thiazol-4-yl)-3-(piperidin-3-yl)urea (target compound III-1)

[0412] Under ice bath, the intermediate III-1-pro1 (77 mg, 0.14 mmol) was dissolved in dioxane (2 mL), 4N hydrogen chloride dioxane solution (2 mL) was added, and stirred at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure, saturated sodium carbonate (5 mL) and dichloromethane (5 mL*3) were added for extraction, the organic phases were combined, washed with saturated brine (5 mL), and concentrated under reduced pressure to obtain 58 mg of crude product of the target compound III-1, with a yield of 92.3%.

[0413] ESI-MS: m / z = 442.0 [M + H] + .

[0414] Step 3: Preparation of formate salt of (R)-1-(2-(4-(cyclobutylmethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)thiazol-4-yl)-3-(piperidin-3-yl)urea (formate salt of target compound III-1)

[0415] The crude product of the target compound III-1 was separated by fully preparative liquid chromatography (column: Shim-pack GIST C18 5μm*20*250mm; mobile phase: A: water (0.1% formic acid v / v), B: acetonitrile; B%: 10%-100%, 20min) to obtain 35 mg of the formate salt of the target compound III-1 as a white solid.

[0416] ESI-MS: m / z = 442.0 [M + H] + .

[0417] Example 28, Preparation of (S)-1-(2-(4-(cyclobutylmethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)thiazol-4-yl)-3-(1-methylpiperidin-3-yl)urea (target compound III-2) and its formate

[0418]

[0419] Step 1: Synthesis of (S)-1-(2-(4-(cyclobutylmethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)thiazol-4-yl)-3-(1-methylpiperidin-3-yl)urea (target compound III-2)

[0420] Compound I-19 (60 mg, 0.14 mmol) was dissolved in dichloromethane (4 mL), and a formaldehyde aqueous solution (30 μL, 0.41 mmol) and a drop of glacial acetic acid were added dropwise. After stirring at room temperature for 4 h, sodium cyanoborohydride (10 mg, 0.16 mmol) was added, and the reaction solution was stirred at room temperature overnight. After the reaction was complete, a saturated sodium carbonate aqueous solution (5 mL) and water (10 mL) were added, and the aqueous layer was extracted with dichloromethane (10 mL*2), and the organic phases were combined, dried over anhydrous sodium sulfate, and spin-dried to obtain 48 mg of the crude product of the target compound III-2, with a yield of 77.4%.

[0421] ESI-MS: m / z = 456.0 [M + H] + .

[0422] Step 2: Preparation of formate salt of (S)-1-(2-(4-(cyclobutylmethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)thiazol-4-yl)-3-(1-methylpiperidin-3-yl)urea (formate salt of target compound III-2)

[0423] The crude product of the target compound III-2 was separated by fully preparative liquid chromatography (column: Shim-pack GIST C18 5μm*20*250mm; mobile phase: A: water (0.1% formic acid v / v), B: acetonitrile; B%: 10%-100%, 20min) to obtain 35 mg of the formate salt of the target compound III-2 as a white solid.

[0424] ESI-MS: m / z = 456.0 [M + H] + .

[0425] Example 29, Preparation of (S)-1-(2-(4-(cyclobutylmethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)thiazol-4-yl)-3-(piperidin-3-yl)urea (target compound III-3) and its formate

[0426]

[0427] Step 1: Synthesis of (S)-1-(2-(4-(cyclobutylmethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)thiazol-4-yl)-3-(piperidin-3-yl)urea (target compound III-3)

[0428] Compound I-19 (60 mg, 0.14 mmol) was dissolved in dichloromethane (4 mL), and N, N-diisopropylethylamine (44 mg, 0.34 mmol) and 2,2-difluoroethyl trifluoromethanesulfonate (35 mg, 0.16 mmol) were added dropwise in sequence, and the mixture was stirred at room temperature for 8 h. The system was extracted with water (10 mL) and dichloromethane (10 mL*2), and the organic phases were combined, dried over anhydrous sodium sulfate, and 52 mg of the target compound III-3 was obtained after spin drying, with a yield of 75.7%.

[0429] ESI-MS: m / z = 506.0 [M+H] + .

[0430] Step 2: Preparation of formate salt of (S)-1-(2-(4-(cyclobutylmethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)thiazol-4-yl)-3-(piperidin-3-yl)urea (formate salt of target compound III-3)

[0431] The product from the previous step was separated by fully preparative liquid chromatography (column: Shim-pack GIST C18 5μm*20*250mm; mobile phase: A: water (0.1% formic acid v / v), B: acetonitrile; B%: 10%-100%, 20min) to obtain 40mg of the formate salt of the target compound III-3 as a yellow solid.

[0432] ESI-MS: m / z = 506.0 [M+H] + .

[0433] Example 30, Preparation of (S)-1-(1-acetylpiperidin-3-yl)-3-(2-(4-(cyclobutylmethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)thiazol-4-yl)urea (target compound III-4)

[0434]

[0435] Compound I-19 (60 mg, 0.14 mmol) was dissolved in anhydrous dichloromethane (4 mL), triethylamine (34 mg, 0.34 mmol) was added, acetyl chloride (13 mg, 0.16 mmol) was added dropwise under ice bath, and the mixture was stirred at room temperature for 5 h. The system was extracted with saturated sodium bicarbonate solution (10 mL) and dichloromethane (10 mL*2), the organic phases were combined, dried over anhydrous sodium sulfate, and spin-dried, and the residue was separated by full preparative liquid chromatography (column: Shim-pack GIST C18 5μm*20*250mm; mobile phase: A: water (0.1% formic acid v / v), B: acetonitrile; B%: 10%-100%, 20 min), and 45 mg of the target compound III-4 was obtained as a white solid with a yield of 68.4%.

[0436] ESI-MS: m / z = 484.0 [M+H] + .

[0437] Example 31, Preparation of 1-(2-(4-(cyclobutylmethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)thiazol-4-yl)-3-(piperidin-4-yl)urea (target compound III-5) and its formate

[0438]

[0439] The preparation method of the target compound III-5 refers to the preparation method of III-1 in Example 27, except that the intermediate C-2 is replaced by the intermediate C-3. The other intermediate materials and preparation method are the same as steps 1 to 2 of the preparation method of Example 27 to obtain a crude product of the target compound III-5.

[0440] ESI-MS: m / z = 442.1 [M+H] + .

[0441] The crude product of the same target compound III-5 was separated by fully preparative liquid chromatography (column: Shim-pack GISTC18 5μm*20*250mm; mobile phase: A: water (0.1% formic acid v / v), B: acetonitrile; B%: 10%-100%, 20min) to obtain the formate salt of the target compound III-5 with a total yield of 51.3% as a white solid.

[0442] ESI-MS: m / z = 442.1 [M+H] + .

[0443] Example 32, Preparation of (S)-1-(2-(4-(cyclobutylmethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)thiazol-4-yl)-3-(2-oxopiperidin-3-yl)urea (target compound III-6)

[0444]

[0445] The preparation method of the target compound III-6 refers to the preparation method of III-1-pro1 in Example 27, except that the intermediate C-2 is replaced by the intermediate C-4, and the other intermediate materials and preparation method are the same as step 1 of the preparation method of Example 27, to obtain 61 mg of the target compound III-6 as a white solid, with a yield of 66.9%.

[0446] ESI-MS: m / z = 456.0 [M + H] + .

[0447] Example 33, Preparation of 1-(2-(4-(cyclobutylmethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)thiazol-4-yl)-3-(pyrrolidin-3-ylurea) (target compound III-7) and its formate

[0448]

[0449] The preparation method of the target compound III-7 refers to the preparation method of III-1 in Example 27, except that the intermediate C-2 is replaced by the intermediate C-5. The other intermediate materials and preparation method are the same as steps 1 to 2 of the preparation method of Example 27 to obtain a crude product of the target compound III-7.

[0450] ESI-MS: m / z = 428.0 [M+H] + .

[0451] The crude product of the same target compound III-7 was separated by fully preparative liquid chromatography (column: Shim-pack GISTC18 5μm*20*250mm; mobile phase: A: water (0.1% formic acid v / v), B: acetonitrile; B%: 10%-100%, 20min) to obtain the formate salt of the target compound III-7 with a total yield of 44.1% as a white solid.

[0452] ESI-MS: m / z = 428.0 [M+H] + .

[0453] Example 34. Preparation of 1-(2-(4-(cyclobutylmethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)thiazol-4-yl)-3-(6-methylpyridin-3-yl)urea (III-8)

[0454]

[0455] The preparation method of the target compound III-8 refers to the preparation method of III-1-pro1 in Example 27, except that the intermediate C-2 is replaced by the intermediate C-6. The other intermediate materials and preparation method are the same as step 1 of the preparation method in Example 27 to obtain the target compound III-8 as a white solid.

[0456] ESI-MS: m / z = 450.0 [M + H] + .

[0457] Example 35. Preparation of target compounds III-9 to III-15

[0458] The preparation method of the target compounds III-9 to III-15 refers to the preparation method of III-1-pro1 in Example 27, except that the raw material C-2 is replaced by C-7 to C-13, and the other intermediate materials and preparation methods are the same as those of III-1-pro1, as shown in the following table:

[0459]

[0460] Example 36, Preparation of (S)-1-(2-(4-(cyclobutylmethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-5-methylthiazol-4-yl)-3-(piperidin-3-yl)urea (target compound IV-1) and its formate

[0461]

[0462] Step 1: Synthesis of (S)-tert-butyl 3-(3-(2-bromo-5-methylthiazol-4-yl)ureido)piperidine-1-carboxylate (Intermediate H-1)

[0463] The preparation method of intermediate H-1 is similar to that of intermediate C-1, except that 2-bromothiazole-4-carboxylic acid is replaced by 2-bromo-5-methylthiazole-4-carboxylic acid, and a white solid is obtained by Curtius rearrangement.

[0464] ESI-MS: m / z = 419.0 [M+H] + .

[0465] 1 H NMR (400MHz, DMSO-d6): 8.24 (s, 1H), 6.49 (d, J = 7.6Hz, 1H), 3.51 (s, 3H), 3.08 (s, 2H),2.20(s,2H),1.82-1.79(m,1H),1.64-1.61(m,1H),1.41(s,2H),1.37(s,9H).

[0466] Step 2: Synthesis of (S)-tert-butyl 3-(3-(2-(4-(cyclobutylmethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-5-methylthiazol-4-yl)ureido)piperidine-1-carboxylate (Intermediate J-1)

[0467] Add intermediate B-14 (68 mg, 0.20 mmol), intermediate H-1 (109 mg, 0.26 mmol), [1,1'-bis(diphenylphosphino)ferrocene] palladium dichloride (14 mg, 0.02 mmol) and potassium carbonate (83 mg, 0.60 mmol) to the flask in sequence, replace nitrogen three times, add dioxane (5 mL), water (1 mL) and react at 100 ° C for 3 hours. After the reaction solution is cooled, add 5 mL of water, extract with ethyl acetate (5 mL*3), combine the organic phases, dry and concentrate, and separate the residue by column chromatography, eluent 0-20% ethyl acetate: petroleum ether, to obtain 69 mg of oil, yield 61.9%.

[0468] ESI-MS: m / z = 556.0 [M+H] + .

[0469] Step 3: Synthesis of (S)-1-(2-(4-(cyclobutylmethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-5-methylthiazol-4-yl)-3-(piperidin-3-yl)urea (target compound IV-1)

[0470] Under ice bath, the intermediate J-1 (69 mg, 0.12 mmol) was dissolved in dioxane (2 mL), and 4N hydrogen chloride dioxane solution (2 mL) was added, and stirred at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure, and saturated sodium carbonate (5 mL) and dichloromethane (5 mL*3) were added for extraction. The organic phases were combined, washed with saturated brine (5 mL), and concentrated under reduced pressure to obtain 42 mg of crude product of the target compound IV-1, with a yield of 74.2%.

[0471] ESI-MS: m / z = 456.0 [M + H] + .

[0472] Step 4: Preparation of formate salt of (S)-1-(2-(4-(cyclobutylmethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-5-methylthiazol-4-yl)-3-(piperidin-3-yl)urea (formate salt of target compound IV-1)

[0473] The crude product of the target compound IV-1 was separated by fully preparative liquid chromatography (column: Shim-pack GIST C18 5μm*20*250mm; mobile phase: A: water (0.1% formic acid v / v), B: acetonitrile; B%: 10%-100%, 20min) to obtain 28 mg of the formate salt of the target compound IV-1 as a white solid.

[0474] ESI-MS: m / z = 456.0 [M + H] + .

[0475] Example 37, Preparation of (S)-1-(2-(4-(cyclobutylmethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-5-fluorothiazol-4-yl)-3-(piperidin-3-yl)urea (target compound IV-2) and its formate

[0476]

[0477] The preparation method of the target compound IV-2 is based on the preparation method of IV-1 in Example 36, except that the raw material 2-bromo-5-methylthiazole-4-carboxylic acid is replaced with 2-bromo-5-fluorothiazole-4-carboxylic acid, and the other intermediate materials and preparation method are the same as steps 1 to 3 of the preparation method of Example 36 to obtain a crude product of the target compound IV-2.

[0478] ESI-MS: m / z = 460.0 [M + H] + .

[0479] The crude product of the same target compound IV-2 was separated by fully preparative liquid chromatography (column: Shim-pack GISTC18 5μm*20*250mm; mobile phase: A: water (0.1% formic acid v / v), B: acetonitrile; B%: 10%-100%, 20min) to obtain the formate salt of the target compound IV-2 as a white solid.

[0480] ESI-MS: m / z = 460.0 [M + H] + .

[0481] Example 38, Preparation of (S)-1-(5-cyano-2-(4-(cyclobutylmethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)thiazol-4-yl)-3-(piperidin-3-yl)urea (target compound IV-3) and its formate

[0482]

[0483] The preparation method of the target compound IV-3 is based on the preparation method of IV-1 in Example 36, except that the raw material 2-bromo-5-methylthiazole-4-carboxylic acid is replaced with 2-bromo-5-cyanothiazole-4-carboxylic acid, and the other intermediate materials and preparation method are the same as steps 1 to 3 of the preparation method of Example 36 to obtain a crude product of the target compound IV-3.

[0484] ESI-MS: m / z = 467.0 [M+H] + .

[0485] The crude product of the same target compound IV-3 was separated by fully preparative liquid chromatography (column: Shim-pack GISTC18 5μm*20*250mm; mobile phase: A: water (0.1% formic acid v / v), B: acetonitrile; B%: 10%-100%, 20min) to obtain the formate salt of the target compound IV-3 as a white solid.

[0486] ESI-MS: m / z = 467.0 [M+H] + .

[0487] Example 39, Preparation of (S)-1-(2-(4-(cyclobutylmethyl)-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl)-5-(trifluoromethyl)thiazol-4-yl)-3-(piperidin-3-yl)urea (target compound IV-4) and its formate

[0488]

[0489] The preparation method of the target compound IV-4 is based on the preparation method of IV-1 in Example 36, except that the raw material 2-bromo-5-methylthiazole-4-carboxylic acid is replaced with 2-bromo-5-trifluoromethylthiazole-4-carboxylic acid, and the other intermediate materials and preparation method are the same as steps 1 to 3 of the preparation method of Example 36 to obtain a crude product of the target compound IV-4.

[0490] ESI-MS: m / z = 510.0 [M+H] + .

[0491] The crude product of the same target compound IV-4 was separated by fully preparative liquid chromatography (column: Shim-pack GISTC18 5μm*20*250mm; mobile phase: A: water (0.1% formic acid v / v), B: acetonitrile; B%: 10%-100%, 20min) to obtain the formate salt of the target compound IV-4 as a white solid.

[0492] ESI-MS: m / z = 510.0 [M+H] + .

[0493] Example 40: Inhibitory activity of the compounds of the present invention on Polθ

[0494] Preparation of compound solution: Dissolve the compound in DMSO, and then use test buffer (25mM Tris-HCl pH7.5, 12.5mM NaCl, 0.5mM MgCl2, 5% glycerol, 0.01% Triton X-100, 0.01% BGG and 1mM DTT) to dilute the compound to be tested 3-fold to obtain 8 concentrations of compound solution, with 1% DMSO as the blank control solution.

[0495] The Picogreen assay was used to test the ability of compounds to bind and inhibit Polθ activity in vitro. Polθ enzyme and primer-template double-stranded (PTD) solution and dNTP working solution were prepared in the test buffer. 1 μL of compound solution of each gradient concentration was added to a 384-well plate, centrifuged, and then 5 μL of Polθ enzyme and primer-template double-stranded (PTD) solution and reaction buffer were added. After centrifugation and incubation at room temperature, 5 μL of dNTP working solution was added to each well, centrifuged, and then incubated at room temperature. After that, the diluted Picogreen was added to terminate the reaction. After 1 hour, the luminescence intensity was measured using a microplate reader (excitation wavelength 485 nm, emission wavelength 520 nm), and the inhibition rate and IC were calculated. 50 value.

[0496] Inhibition rate (%) = (Max-Signal) / (Max-Min)*100%, Max represents the luminescent signal intensity of the positive control well without adding the compound; Min represents the luminescent signal intensity of the negative control well without adding the enzyme, and Signal represents the luminescent signal intensity of the compound to be tested.

[0497] The test results are shown in the table below:

[0498] Compd <![CDATA[PolθIC 50 (nM)]]> Compd <![CDATA[PolθIC 50 (nM)]]> I-2 ++++ I-3 ++ I-4 + I-5 + I-8 ++ I-9 ++++ I-10 ++ I-11 ++ I-12 ++++ I-13 +++ I-14 + I-16 + I-17 +++ I-19 ++++ I-20 + I-22 +++ I-24 + II-1 ++++ II-3 +++++ II-4 +++++ II-13 +++++ III-1 ++++ III-2 +++++ III-3 ++++ III-8 +++++ III-10 ++++ IV-1 ++++ IV-2 ++++ Control compound 1 ++ Control compound 2 ++ Control compound 3 +++ Control compound 4 +++

[0499]

Note

[0500] “++++” represents ≤10 nM;

[0501] “++++” represents ≤50nM, but >10nM;

[0502] “+++” represents ≤100 nM, but >50 nM;

[0503] “++” represents ≤500nM, but >100nM;

[0504] “+” represents >500 nM.

[0505] It can be seen from the data in the table that most compounds exhibit excellent Polθ inhibitory activity and have good application prospects.

Claims

1. A thiazole urea derivative represented by formula (I) and its isomers, solvates, isotopic derivatives or pharmaceutically acceptable salts thereof: R 1 is selected from 4-12 membered heterocyclic group, 5-14 membered heteroaryl group or C 6-12 Aryl; the 4-12 membered heterocyclic group, 5-14 membered heteroaryl and C 6-12 The aryl group is unsubstituted or substituted by one or more of the following substituents: halogen, cyano, hydroxyl, difluoromethoxy, trifluoromethoxy, amino, thiol, trifluoromethylthio, oxo, -NH-C(O)C 1-6 Alkyl, -NH-C(O)-C 3-6 Cycloalkyl, -C(O)C 1-3 Alkyl, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkylsulfone, C 1-6 Alkylamino, C 1-6 Alkylthio, 4-10 membered heterocyclic group, C 6-12 Aryl, 5-14 membered heteroaryl; R 2 and R 3 are each independently selected from hydrogen, C 1-6 Alkyl or C 3-6 Cycloalkyl; R 4 is selected from hydrogen, halogen, cyano, hydroxy, difluoromethoxy, trifluoromethoxy, amino, C 1-6 Alkyl, C 3-8 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkylsulfone, C 1-6 Alkylamino, C 1-6 Alkylthio, 4-6 membered heterocyclic group; Ring A is selected from: Ring B is selected from a benzene ring, a pyridine ring, a pyrimidine ring, a pyrazine ring or a pyridone ring; R 5 Selected from halogen, cyano, hydroxyl, amino, thiol, oxo, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 1-6 Alkylthio, C1-6 Alkylsulfone, C 6-12 aryl, 4-10 membered heterocyclyl or 5-14 membered heteroaryl; said C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 1-6 Alkylthio, C 1-6 Alkylsulfone, 4-10 membered heterocyclic group, C 6-12 Aryl and 5-14 membered heteroaryl are unsubstituted or substituted by one or more of the following substituents: halogen, cyano, hydroxyl, thiol, amino, oxo, -NH-C(O)C 1-3 Alkyl, -C(O)NH2, -C(O)-NH-C 1-3 Alkyl, -C(O)C 1-3 Alkyl, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-8 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkylamino, C 1-6 Alkylthio, C 1-6 Alkylsulfone, C 6-12 Aryl, C 6-12 Aryl, 4-10 membered heterocyclyl or 5-14 membered heteroaryl; n is selected from 0, 1, 2, 3, 4 or 5.

2. The thiazolyl urea derivative according to claim 1, characterized in that: R 1 Selected from:

3. The thiazolyl urea derivative according to claim 1, characterized in that: R 2 and R 3 are each independently selected from hydrogen; R 4 is selected from hydrogen, fluorine, methyl, cyano, difluoromethyl or trifluoromethyl.

4. The thiazolyl urea derivative according to claim 1, characterized in that: Ring B in ring A is preferably selected from a benzene ring or a pyridine ring.

5. The thiazolyl urea derivative according to claim 1, characterized in that: R 5 Selected from:

6. The thiazolyl urea derivative according to any one of claims 1 to 5, characterized in that A compound having the following general structural formula (I) or a pharmaceutically acceptable salt thereof: In the formula, R 2 and R 3 are each independently selected from hydrogen or C 1-6 alkyl; Ring A is selected from: Wherein, * indicates that ring A is connected to the thiazole ring.

7. The thiazolyl urea derivative according to any one of claims 1 to 6, characterized in that Preferably selected from the following structures:

8. A pharmaceutical composition comprising the thiazolyl urea derivative and its isomer, solvate, isotope derivative or pharmaceutically acceptable salt as claimed in any one of claims 1 to 7 as an active ingredient, and one or more pharmaceutically acceptable carriers.

9. Use of the thiazolyl urea derivative according to any one of claims 1 to 7 or the pharmaceutical composition according to claim 8 in the preparation of drugs for Polθ-mediated diseases.

10. The use according to claim 9, characterized in that The drug is used for treating cancer or tumor-related diseases in mammals.

11. The thiazole urea derivative according to any one of claims 1 to 7, or the pharmaceutical composition according to claim 8 can be used in combination with one, two or more other anticancer agents or immune checkpoint regulators or therapeutic methods (such as radiotherapy) for treating cancer or tumors; preferably, the other anticancer agents or immune checkpoint regulators for treating cancer or tumors include PARP inhibitors, ATR inhibitors, ATM inhibitors, WEE1 inhibitors, topoisomerase inhibitors and DNA damaging chemotherapeutics; preferably, the DNA damaging chemotherapeutics include cisplatin, bleomycin, gemcitabine, docetaxel; the topoisomerase inhibitors include etoposide and irinotecan.

Citation Information

Patent Citations

  • Heterocyclic compounds for use in the treatment of cancer

    WO2021028643A1

  • Novel therapeutic use

    WO2021028644A1

  • Deuterated compounds for use in the treatment of cancer

    WO2021028670A1

Cited By

  • Aromatic heterocyclic pyrrolidone derivative and use thereof

    WO2025003769A3